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force-induced unfolding of VWF is the only mechanism to enhance proteolysis by ADAMTS13, or if
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ADAMTS13 yielded ADAMTS13 variants with reduced inhibition by autoantibodies and enhanced specific
activity. Finally, we have demonstrated that infusion of ADAMTS13 and a truncated variant into
ADAMTS13-/- mice can restore the thrombus composition and kinetics of fibrin and platelet accumulation in
an arterial thrombosis model. Together, these results suggest an important physiological role of cofactor
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ABSTRACT 
REGULATION OF ADAMTS13 FUNCTION IN HEMOSTASIS BY COFACTOR 
AND SUBSTRATE EXOSITE INTERACTIONS 
Christopher Gemil Skipwith 
X. Long Zheng, M.D., Ph.D. 
 
ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type1 repeats-
13) is an enzyme that is mainly synthesized in the liver and secreted into the blood 
stream. In plasma, ADAMTS13 cleaves ultralarge (UL) von Willebrand factor (VWF) 
newly released from stimulated and/or injured endothelial cells. It also cleaves soluble 
UL-VWF and VWF in flowing blood or at the site of growing thrombi under high shear 
stress. The basic enzymology and structure-function of the ADAMTS13-VWF interaction 
have presented many interesting questions, particularly in the context of physiological 
cofactors and fluid shear stress. The relatively poor understanding of this system reflects 
the complex assessment of VWF proteolysis, as VWF in solution exhibits a conformation 
that does not actively engage with ADAMTS13. It has been unclear whether force-
induced unfolding of VWF is the only mechanism to enhance proteolysis by 
ADAMTS13, or if interactions of ADAMTS13 and VWF with cofactors ideally position 
ADAMTS13 on VWF multimers for enhanced cleavage. We demonstrated that 
coagulation factor VIII (FVIII) and blood platelets cooperatively accelerate proteolytic 
cleavage of soluble VWF by ADAMTS13 through an alteration of VWF substrate 
conformation under physiologically relevant fluid shear stresses.  In addition, we have 
established the critical role of the VWF propeptide and FVIII- and platelet-binding 
vi 
 
domains of VWF in regulating proteolysis of VWF by ADAMTS13 under 
physiologically relevant shear stress. Through site-directed mutagenesis, kinetic analyses, 
and peptide inhibition assays we have identified a substrate-binding exosite containing 
ADAMTS13 residues Arg659, Arg660 and Tyr661 that exhibits an important role in 
proteolytic cleavage of VWF under both non-physiological and physiological conditions. 
In addition, modification of this exosite region of ADAMTS13 yielded ADAMTS13 
variants with reduced inhibition by autoantibodies and enhanced specific activity. Finally, 
we have demonstrated that infusion of ADAMTS13 and a truncated variant into 
Adamts13-/- mice can restore the thrombus composition and kinetics of fibrin and platelet 
accumulation in an arterial thrombosis model. Together, these results suggest an 
important physiological role of cofactor binding to VWF and VWF interactions with 
ADAMTS13 exosites in regulating ADAMTS13 function in hemostasis. 
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CHAPTER 1: INTRODUCTION  
 
1.1 Overview 
The coagulation system includes soluble and cellular factors that operate in concert to 
prevent hemorrhage.  For the coagulation system to serve the needs of the organism, the 
fluidity of blood must be maintained under physiologic situations and clotting must be 
promoted only when and where there is a threat of vascular interruption by trauma. This 
process of maintenance of normal blood flow is termed hemostasis, whereby the system is 
maintained in a constant anticoagulant state1. 
 
1.2 Maintenance of Hemostasis 
1.2.1 The vascular endothelium 
The vascular endothelium is strategically located at the interface between the tissues and 
blood. It is pivotal for protecting against vascular injury and maintaining blood fluidity. 
Disruption of the vascular endothelium results in loss of the anticoagulant state. In 
addition to the loss of anticoagulant function, disruption of the endothelium exposes the 
subendothelial cell matrix, which contains collagen, von Willebrand factor (VWF) and 
other substances to which circulating platelets bind1,2,3.  Trauma also directly stimulates 
the expression of procoagulant activity by endothelial cells3. 
 
1.2.2 Platelet aggregation as a hemostatic mechanism 
Platelet aggregates bound to the subendothelium serve to reinforce the effect of 
vasoconstriction by interrupting the loss of blood at sites of trauma4.  This “platelet plug” 
2 
 
is physically unstable and is often insufficient by itself to permanently arrest bleeding4, 
which is why the process of clot formation is critical.  Activated platelets accelerate the 
rate at which clotting occurs compared with reaction rates in plasma by provide binding 
sites for the clotting proteins, concentrating and orienting them on the cell surface in a 
way that enhances their efficient interaction4,5. Activated platelets also promote 
redistribution of anionic phospholipids from the inner to the outer cell membrane where 
they serve as important cofactors for several clotting reactions5. 
 
1.2.3 The coagulation system 
The coagulation system is composed of a series of proteins, most of which are synthesized 
in the liver and circulate in plasma primarily as single chain, inactive precursors (Figure 
1.1)6.  Once the coagulation system has been activated, several of these proteins are 
converted into two-chain, active enzymes.  In turn, these enzymes act upon other specific 
coagulation protein precursors converting them into active enzymes or into active 
cofactors.  Ultimately, the enzyme thrombin is generated, which cleaves fibrinogen to 
fibrin6,7.  Polymerized fibrin is the predominant constituent of the visible clot.  Cell 
surfaces accelerate coagulation reactions dramatically by binding and orienting enzymes, 
substrates and cofactors7.  These cell surfaces may include injured or activated 
endothelium, activated monocytes/macrophages, exposed smooth muscle cells, or 
activated platelets. 
3 
 
 
 
Figure 1.1. The Coagulation Cascade. The coagulation cascade can follow alternative routes 
depending on the initiating factor. The extrinsic pathway is initiated by tissue factor and involves 
calcium ions and factor VII. In the intrinsic pathway, factors XII, XI, IX and VIII are activated by 
exposure to subendothelial collagen or foreign surfaces. Both pathways lead to the activation of 
factor X and proceed along the common pathway, involving factors V, II, I and XIII, to the 
formation of a fibrin clot. 
 
1.3 von Willebrand Factor Plays a Central Role in Hemostasis 
1.3.1 von Willebrand Factor synthesis 
VWF is synthesized in all vascular endothelial cells, and in developing 
megakaryocytes7,8. A 275 kDa monomer of pro-VWF, consisting of the D1-D2-D’-D3-
A1-A2-A3-B-C1-C2-CK domains (Figure 1.2), is initially synthesized in the endoplasmic 
reticulum (pH ~7.4). N-linked glycans are added in the endoplasmic reticulum, most 
disulfide bonds are formed, and pro-VWF is dimerized through formation of inter-
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monomer disulfide bonds in the C-terminal cysteine-knot (CK) domain9. After transport 
to the Golgi (pH ~ 6.2), pro-VWF dimers form homo-polymers or multimers through an 
additional disulfide bond near the amino terminus of the mature subunit, and the 
propeptide is then cleaved from pro-VWF by furin7,8. It is also in the Golgi that N-linked 
glycans are processed and O-linked glycans are added9.  
 
 
Figure 1.2. Schematic representation of pro-VWF. From Zheng and Sadler79. Binding sites are 
indicated for collagen, FVIII, GP1b and integrin αIIbβ3. The cleavage site (Tyr1605-Met1606) 
and inter-subunit disulfide bonds (S-S) are also shown. 
 
1.3.2 Storage and secretion of von Willebrand Factor 
The multimeric VWF is stored in the Weibel-Palade bodies of endothelial cells and α-
granules of platelets. A small fraction of VWF multimers is constitutively secreted from 
endothelial cells9. It has been shown in vitro (with Ca2+ and pH 6.2) that D1-D2 
monomers and D’D3 dimers can assemble into helices with the same dimensions and 
three-dimensional shape as VWF tubules in Weibel-Palade bodies10,11. The ultimate 
purpose of this method of assembly is likely to overcome the challenges of synthesis of a 
long disulfide-linked polymer that can be coiled into a compact form for storage. 
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Figure 1.3.  Biosynthesis, helical assembly, and secretion of VWF multimers. Modified from 
Springer12. Panel A. Primary structure and domain organization of VWF. Cysteines are vertical 
lines and are connected for chemically determined disulphide bonds. N and O-linked glycans are 
closed and open circles, respectively. Panels B-E. Scheme for biosynthesis, helical assembly, and 
secretion. 
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VWF dimers linked by disulfide bonds near the N-terminal end in the D3 domain are 
assembled onto the ends of growing helical tubules in the Weibel-Palade bodies. Pro-
VWF dimers that are nearby have growing tubule ends that place one D’D3 domain 
adjacent to the D’D3 domain of the previously assembled pro-VWF dimer (Figure 1.3). 
The role of this helical assembly is to encourage inter-dimer disulfide bond formation and 
enable furin cleavage between the D2 and D’D3 domains12. It has been shown that the 
organization of VWF dimers in the Weibel-Palade bodies is quite peculiar (Figure 1.4)11. 
Whereas DNA forms structures with two molecules per helix, the VWF helices only 
contain one multimer11. Similar to DNA, however, there is 2-fold symmetry, which 
occurs because of a two-fold axis about the D1, D2, D’D3 dimer (Figure 1.4)11,12. 
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Figure 1.4.  Helical assembly of the N-terminal domains of VWF in the tubules of Weibel-
Palade bodies. Modified from Huang et. al.11. Helical assembly is shown as progressing from 
bottom to top. Each successive pro-VWF dimer is numbered and shown alternately as lighter 
domains outlined in red or darker domains outlined in green. Inter-dimer disulfide crosslinks form 
at the 2-fold symmetry axis between D’D3 domains (red circles). The D1 and D2 domains are 
denoted a and b.  
 
Upon stimulation, VWF is secreted from endothelial cells as ultra-large (UL)-VWF 
multimers that form string-like structures attached to the endothelial cell surface13, 
perhaps through interaction with P-selectin14. Orderly coiling of VWF in Weibel-Palade 
bodies is paramount to proper unraveling of VWF during secretion15. The first step in 
secretion involves formation of a narrow constriction between the plasma membrane and 
the Weibel-Palade bodies. Electron microscopy indicates that secretion occurs from one 
end of a Weibel-Palade body10. After fusion with the plasma membrane, there is an 
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expansion in Weibel-Palade body width and an increase in spacing between the tubules10. 
A reasonable conclusion is that dissociation of the D1-D2 pro-domain, coupled with 
unraveling of VWF multimers, proceeds at the VWF tubules closest to the secretion 
pore12. Given this method of VWF secretion, the process may proceed such that multiple 
VWF multimers are released in parallel. It has been shown that VWF molecules can self-
associate16, and VWF fibrils extend from stimulated endothelial cells in the flow 
direction17. 
 
1.3.3 von Willebrand Factor conformation and length 
Electron microscopy of VWF at pH 7.4 reveals either compact or extended structures18,19. 
Atomic force microscopy (AFM) has demonstrated that, under shear flow, VWF adopts 
an extended conformation20. The domain organization can be described as variably-sized 
beads spaced close together on a flexible string. This structure is interrupted by thin 
interdomain segments, such as O-glycosylated segments on either side of the A1 domain 
(Figure 1.3)12. An estimate of the monomer size is about 60-70 nm based on the average 
spacing observed between domains18. VWF is highly flexible at pH 7.419, permitting 
dynamic, rapid changes in multimer shape under flow conditions. 
SDS-agarose of VWF suggests that larger multimers consist of 14-20 dimers18. Electron 
microscopy shows longer VWF multimers that can consist of 30 dimers18. Under shear 
flow, fluorescent-labeled VWF molecules can extend up to 15 µm21. Combining these 
measurements with the previously-mentioned monomer size of 60-70 nm, one can 
estimate that there are 60–250 monomers per multimer12. It has been reported that there is 
a 50-fold expansion in length between stored VWF and the extended form seen by 
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electron microscopy11. Thus, a 5 µm long Weibel-Palade body tubule would yield a 
250 µm long molecule of VWF, which is highly concordant with the observation of 100-
1000 µm VWF strings after secretion from endothelial cells in vitro13.  
 
1.3.4 The effect of flow on von Willebrand Factor conformation 
The conformation of VWF after release is governed by fluid dynamics in vascular 
systems. The most common type of flow encountered by VWF is shear flow. In shear 
flow, the rate of fluid flow increases from the wall toward the center of the vessel (Figure 
1.5). This system exhibits laminar flow, which dictates that the velocity of each lamina 
increases from negligible at the wall to maximal at the center of the vessel (Figure 
1.5)22,23. Conversely, the shear rate is highest at the wall. The shear flow experienced by 
VWF is a combination of rotational flow and elongational flow23. Rotational flow causes 
particles to tumble, whereas elongational flow causes particles to adapt elongated 
conformations22. VWF multimers have a compact shape18,19,21,26 however in flow VWF 
elongates and tumbles20,21,26. 
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Figure 1.5. Shear flow in vessels. In shear flow, the rate of fluid flow increases from the wall 
toward the center of the vessel. This system exhibits laminar flow, where the velocity of each 
lamina increases from negligible at the wall to maximal at the center of the vessel. The shear rate 
is highest at the wall.  
 
This remarkable behavior of VWF under flow makes it such that VWF is most extended 
where its hemostatic functions are required. Because shear stress is greatest at the vessel 
wall, VWF which has been recruited to the sub-endothelial matrix experiences forces that 
are much greater than free-flowing VWF12,14, suggesting that the forces experienced are 
solely elongational26.  
 
1.3.5 The interaction of von Willebrand Factor with other molecules 
Coagulation Factor VIII 
VWF binds factor VIII (FVIII), a clotting cofactor, and stabilizes it in the circulation. 
Factor VIII, which is synthesized as a 2,351 amino acid single-chain glycoprotein, binds 
VWF with high affinity (KD<0.5 nM) through its D’D3 domain27. The domains of FVIII 
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are organized as A1-A2-B-A3-C1-C2 (Figure 1.6). The mature protein has a molecular 
weight of 280 kDa composed of a light chain and a heavy chain28. The light chain has a 
molecular weight of 80 kDa and is made up of domains A3-C1-C2, while the heavy chain 
is composed of domains A1-A2-B and has a more heterogeneous composition with 
molecular weights varying from 90 – 200 kDa28.  
 
 
 
Figure 1.6. Molecular Structure of human factor VIII and thrombin cleavage. Schematic 
representation of the domain structure of FVIII. The heavy chain composed of A1–A2 domains is 
linked to a heterogeneously processed B domain of variable length. The light chain is composed 
of A3–C1–C2 domains. The three acidic regions are denoted as a1, a2, and a3. Upon activation 
by thrombin, FVIII is released from VWF, after which thrombin cleaves FVIII after Arg residues 
372, 740, and 1689. Dissociation of FVIII from VWF is facilitated by the cleavage after Arg-
1689. Cleavage after Arg-740 releases the dispensable B chain while cleavage after Arg-372 
allows the A1 domain to separate from the A2 domain. 
 
FVIII circulates in plasma at levels of approximately 200 ng/ml27,28. In vivo, a 1:50 ratio 
of FVIII to VWF is constantly and rigorously maintained. VWF primarily serves to 
stabilize the FVIII and promote the association of the light and heavy chains of FVIII 
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through a non-covalent complex which persists until the FVIII is activated by thrombin28. 
The VWF-bound FVIII is protected from being inactivated by activated factor IX, 
activated factor X and activated protein C29,30 and antibodies against FVIII31. 
Upon activation by thrombin, FVIII is released from VWF27, after which thrombin 
cleaves FVIII after Arg residues 372, 740, and 168932. Dissociation of FVIII from VWF 
is facilitated by the cleavage after Arg-168932. Cleavage after Arg-740 releases the 
dispensable B chain while cleavage after Arg-372 allows the A1 domain to separate from 
the A2 domain28,32. Activated FVIII (FVIIIa) accelerates the rate of FX activation by 
FIXa and eventually leads to the formation of a blood clot. 
 
Platelets 
VWF also binds platelets (Figure 1.7) through interaction with the platelet receptor 
glycoprotein Ibα of the GP1b-IX-V receptor complex in the VWF A1 domain33,34,35, and 
interactions of the VWF C-domains with integrins αIIbβ336,37 and αVβ338,39. The ligand-
binding site for VWF is located within the 45-kDa N-terminal region of GP1bα34,35. The 
GP1bα receptor is expressed on the platelet surface in a functional state that requires no 
prior activation to bind VWF. After initial platelet arrest due to GP1ba-VWF interaction, 
intracellular signaling occurs and the platelets become activated34. This leads to 
conformational change and engagement of further receptors and the presentation of 
phosphatidylserine (PS) on the platelet membrane. Upon ligand binding, the GP1b-IX-V 
receptor complex can induce signals leading to calcium mobilization, the rearrangement 
of the cytoskeleton, granule release, and activation of αIIbβ3 integrins33,34,35,39. 
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Figure 1.7. Platelet surface receptors. Normal hemostasis in response to vascular injury is 
initiated by exposure of subendothelial matrix, allowing VWF and collagen access to their 
platelet receptors, GPIb-IX-V and GPVI. These interactions lead to rapid elevation of cytosolic 
Ca2+, cytoskeletal rearrangements, and activation of αIIbβ3 that binds VWF or fibrinogen and 
mediates platelet aggregation. 
 
There is a strong correlation between the effects of hydrodynamic flow on VWF 
elongation and platelet aggregation. Studies have shown that VWF adsorbed to the wall 
of a flow chamber adheres to platelets through GPIbα37. The binding site for GP1bα in 
the A1 domain appears to be hidden or cryptic under static conditions, and exposed by 
flow12,33,34. The D’D3 domain has been shown to shield recognition of platelets by the A1 
domain40. VWF length may potentiate binding to GP1bα on platelets by enhancing shear 
or elongational flow-dependent extension of VWF. The avidity of GP1bα to VWF is also 
modulated by flow37. Multivalent binding sites are better exposed in the extended 
conformation of VWF, as opposed to its compacted conformation. Furthermore, platelets 
have a greater hydrodynamic surface area than VWF39, which effectively increases the 
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elongational force on VWF. This results in a positive feedback mechanism for amplifying 
hemostasis. 
 
Collagen 
VWF has also been shown to bind sub-endothelial collagens through the VWF A1 and 
A3 domains41. VWF mediates the adhesion of platelets to exposed subendothelium by 
forming a bridge between collagen, heparin-like glycosaminoglycans and other 
components of the subendothelium.  Several types of fibrillar collagen are bound by 
VWF in vitro42, and the major collagen binding site is within VWF domain A341, while a 
second site may be present in the A1 domain43. Non-fibrillar collagen type VI binds 
domain A1 rather than domain A342. In addition, monoclonal antibodies can prevent 
VWF binding to fibrillar collagen or subendothelial connective tissue, but not both41,43. 
VWF can be deposited on collagen substrates under static conditions41, however it has 
also been shown that the shear thresholds for VWF extension and deposition on collagen 
substrates are superimposable21, indicating that, unlike platelet binding, VWF binding to 
collagen may not be dependent on hydrodynamic flow. 
 
1.3.6 Molecular structure of von Willebrand Factor 
The current understanding of the organization and boundaries of domains in VWF 
remains imperfect. Only the 3 A domains (A1, A2, A3) are well characterized with 
determined crystal structures44,45,46. The VWF A domains are the defining members of 
the VWA protein fold and family47. They have a central hydrophobic β-sheet with 6 β-
strands, surrounded typically by 6 amphipathic α-helices (Figure 1.8). VWF A-like 
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domains are also found in integrins as ligand-binding αI and βI domains44,45, in 
complement components47, and in intracellular proteins with diverse functions47. Some 
VWF A-like domains contain a metal-ion dependent adhesion site, but those in VWF do 
not12,47. VWF A-like domains in integrins and complement undergo substantial 
conformational changes that regulate affinity for ligand47. Conformational change in 
VWF A domains has not yet been observed. VWF A1 and integrins differ substantially in 
the location of ligand binding sites on the surfaces of the VWF A-like domains. Most 
modules in extracellular proteins are all-β44,45, and have their N- and C-terminal ends at 
opposite ends of the domain. In contrast, VWF A-like domains are α/β, and their N- and 
C-termini are adjacent to one another44,46,47, enabling greater flexibility when arranged as 
beads on a string, as in VWF. 
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Figure 1.8.  Crystal structures of the VWF A domains. Panels A-C. Ribbon diagrams for 
VWF-A2, VWF-A2, and VWF-A3, respectively. α-helices (green, blue, cyan), β-strands (yellow) 
and loops (grey) are shown. The primary sequence (denoting secondary structure by the 
Dictionary of protein secondary structure (DSSP) algorithm24) is displayed, showing the 
similarity in the placement of α-helices, β-strands, and 3/10 helices. 
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Unique among VWF domains, A2 lacks a long-range disulfide bond (Figure 1.7) and, 
therefore, is unprotected from unfolding by tensile force applied along the length of VWF 
multimers47. Two 1.9 Å crystal structures of A246,48 have revealed surprising evolutionary 
adaptations to the function of the VWF A2 domain as a “shear bolt” domain (Figure 1.9), 
and how mutations destabilize A2 in von Willebrand Disease (VWD)46,48. The wild-type 
mammalian A2 structure reveals two N-glycosylation sites, as well as a vicinal disulfide 
bond46 whereas the mutant E. coli A2 structure reveals a Ca2+-binding loop48. 
 
 
Figure 1.9.  The VWF A2 domain. Adapted from Emsley et. al.47 and Zhang et. al.48 Ribbon 
diagrams show α-helices (cyan), β-strands (yellow) and loops (grey). The α4-less loop is in 
magenta. Key side chains are shown as sticks, and coordinated Ca2+ is shown as a sphere. 
Carbons of the ADAMTS13 cleavage site residues Tyr1605 and Met1606 are black. The vicinal 
disulfide is in gold. Hydrogen and metal coordination bonds are dashed. 
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1.4 von Willebrand Factor Pathophysiology 
1.4.1 The deficiency or abnormality of VWF causes von Willebrand Disease 
von Willebrand Disease (VWD) is an inherited bleeding disorder that is caused by 
deficiency or dysfunction of VWF. Defects in VWF can cause bleeding by impairing 
platelet adhesion or by reducing the concentration of FVIII. VWD is a relatively common 
cause of bleeding, but the prevalence varies considerably among studies and depends 
strongly on the case definition that is used. VWD prevalence has been estimated in 
several countries on the basis of the number of symptomatic patients seen, and the values 
range from roughly 23 to 110 per million population (0.0023–0.01%)49. 
The patient who led to the discovery of VWD was a 5-year-old girl who was seen by Dr. 
Erik von Willebrand50. He ultimately assessed 66 members of her family and reported, in 
1926, that this was a previously undescribed bleeding disorder that differed from 
hemophilia and exhibited mucocutaneous bleeding, autosomal inheritance, prolonged 
bleeding times, and normal clotting time50. In the 1950s, it became clear that a “plasma 
factor” was decreased in these patients, and the factor was called “von Willebrand 
factor”49. As cryoprecipitate and commercial FVIII concentrates were developed, it was 
recognized that both VWF and antihemophilic factor (FVIII) purified together. 
When immunoassays were developed, persons who had VWD were found to have 
reduced factor VIII-related antigen (FVIIIR:Ag) (which we now refer to as VWF antigen 
(VWF:Ag))51. Characterization of the proteins revealed that FVIII was the clotting 
protein deficient in hemophilia A (HA), and VWF was a separate FVIII carrier protein 
that resulted in the fractionation of both proteins in commercial concentrates51. 
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Furthermore, a deficiency of VWF resulted in increased FVIII clearance because of the 
reduced VWF carrier protein. 
 
1.4.2 Genetics of von Willebrand Disease 
Since the 1980s, molecular and cellular studies have defined HA and VWD more 
precisely. Persons who had VWD had a normal FVIII gene on the X chromosome, but 
some were found to have an abnormal VWF gene on chromosome 1251. Variant forms of 
VWF were recognized in the 1970s, and these variations are now recognized as the result 
of synthesis of an abnormal protein51. Gene sequencing identified many of these persons 
as having a VWF gene mutation. The genetic causes of milder forms of low VWF are 
still under investigation, and these forms may not always be caused by an abnormal VWF 
gene. In addition, acquired disorders may result in reduced or dysfunctional VWF. 
 
1.4.3 Classifications of von Willebrand Disease 
VWD is classified into three major categories: partial quantitative deficiency (type 1), 
qualitative deficiency (type 2) and total deficiency (type 3) (Table 1.1)52,53. Type 2 VWD 
is divided further into four variants (2A, 2B, 2M and 2N) on the basis of details of the 
phenotype. Before publication of the 1994 revised classification of VWD53, VWD 
subtypes were classified using roman numerals (types I, II, and III), generally 
corresponding to types 1, 2 and 3 in the 1994 classification, and within type II several 
subtypes existed (designated by adding sequential letters of the alphabet, i.e. II-A through 
II-I). Most of the latter VWD variants were amalgamated as type 2A in the 1994 
classification, with the exception of type 2B, for which a separate new classification was 
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created. In addition, a new subtype (2M, with “M” representing “multimer”) was created 
to include variants with decreased platelet-dependent function but no significant decrease 
of higher molecular weight VWF multimers54. Subtype 2N VWD was defined, with “N” 
representing “Normandy”, where the first individuals were identified, with decreased 
FVIII because of VWF defects of FVIII binding54. 
Table 1.1. Classification of von Willebrand Disease 
Type Description 
1 Partial quantitative deficiency of VWF 
2 Qualitative VWF defect 
     2A Decreased VWF-dependent platelet adhesion with selective 
deficiency of high-molecular-weight multimers 
     2B Increased affinity for platelet GPIbα 
    2M Decreased VWF-dependent platelet adhesion without 
selective deficiency of high-molecular-weight multimers 
    2N Markedly decreased binding affinity for FVIII 
3 Complete deficiency of VWF 
 
1.4 Structure, Evolution, and Cellular Functions of ADAMTS13 
1.4.1 ADAMTS13 is the von Willebrand Factor-cleaving protease 
Newly released UL-VWF is not only large in size, but also functionally hyperactive. It 
binds platelets with increased affinity55 and causes abnormal platelet adhesion and 
aggregation on endothelial cell surface56. Therefore, proteolytic processing of UL-VWF 
multimers into normal sizes of VWF (from 500 kDa to 2 million Da) circulating in blood 
is critical for preventing arterial thrombosis57. This trimming process is primarily 
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achieved by proteolytic cleavage of VWF by a plasma metalloprotease, ADAMTS13 (A 
Disintegrin and Metalloprotease with Thrombospondin type1 repeats-13)13.  The 
translated product consists of 1,427 amino acid residues with an estimated molecular 
weight of 145 kDa58. It comprises a signal peptide, a propeptide, a metalloprotease 
domain (Met), a disintegrin domain (Dis), first thrombospondin type 1 repeat, a Cys-rich 
domain and a spacer domain (Figure 1.10). The C-terminus of ADAMTS13 has seven 
additional TSP1 repeats and two CUB domains (Figure 1.9)58.  
 
Figure 1.10. Schematic structures of the ADAMTS13 gene and protein.  Modified from 
Zheng et. al.58 ADAMTS13 consists of a signal peptide (S), propeptide (P) and a metalloprotease 
domain, followed by a proximal C-terminal region including disintegrin (Dis), first TSP1 (1), 
Cys-rich (Cys) and spacer domains. The middle and distal C-terminal regions have the 2nd to 8th 
TSP1 repeats and two CUB domains, respectively.  
 
1.4.2 Specificity of ADAMTS13 
The catalytic subunit, known as the metalloprotease domain (Met), contains a 
characteristic HEXXHXXGXXHD sequence that coordinates Zn2+ or Ca2+ binding58. 
However, Met alone is not sufficient for recognition and cleavage of multimeric VWF 
or peptidyl substrates that consist of 73 amino acid residues from the A2 domain (such 
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as GST-VWF7359,60 and FRETS-VWF7359,61). The ancillary domains within the 
proximal C-terminal region of ADAMTS13 including the disintegrin domain (Dis), the 
first TSP1, the Cys-rich domain (Cys) and the spacer domain (Spa) appear to be 
required for recognition and cleavage of VWF under static/denaturing conditions59,61. 
Removal of either domain within the proximal C-terminal region significantly reduces 
the ability of ADAMTS13 to cleave VWF and reduces the specificity59,61.  
Cleavage of peptide substrates, such as GST-VWF73 and FRETS-VWF73, requires 
even fewer domains of ADAMTS1359, suggesting that the interaction between 
ADAMTS13 and full-length VWF is quite different from that between ADAMTS13 and 
peptide substrates. Regardless of the kind of substrate used, it has been demonstrated 
that the Cys/Spa region of ADAMTS13 is critical for recognition of VWF, partly 
through its binding to the amino acid residues (Glu1660-Arg1668) in the VWF-A2 
domain60.  
The role of the more distal C-terminal domains (such as TSP1 repeats and CUB domains) 
of ADAMTS13 in recognition of VWF, however, remains controversial.  Peptides or the 
fragment derived from the first CUB domain of ADAMTS13 inhibited cleavage of 
endothelial cell bound UL-VWF multimers62, but another study showed that an 
ADAMTS13 mutant truncated after Spa was active in cleavage of endothelial cell bound 
UL-VWF using the same assay63. Under physiologically relevant conditions, the 
cooperative activity between the TSP1 5-8 and CUB domains appeared to be critical for 
recognition of soluble VWF under fluid shear stress64, suggesting that binding of the 
middle and distal C-terminal domains of ADAMTS13 may be required for further 
interactions between VWF-A2 and the proximal C-terminal domains such as Cys and 
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Spa. Homozygous mutations found in hereditary TTP resulted in truncation of 
ADAMTS13 four amino acid residues after Spa65, further supporting the role of the 
middle and distal C-terminal domains in ADAMTS13 function in vivo. 
 
1.4.3 Molecular structure of ADAMTS13 
To date, crystal structures of the M and D domains of three human ADAMTS-family 
proteins, ADAMTS166, ADAMTS467 and ADAMTS567, have been reported. The first 
crystal structure of exosite-containing fragments of ADAMTS13 was reported by 
Akiyama et. al68. The structures of the ADAMTS13-DTCS fragment, obtained at 2.6-Å 
and 2.8-Å resolution, revealed linearly distributed exosites that recognize distinct 
substrate regions (Figure 1.11)68. 
The ADAMTS13 cleavage site at residues Tyr1605 and Met1606 lies in a very inaccessible 
site in the folded A2 domain, situated in the center of the β4-strand, sandwiched between 
amphipathic α-helices and loops on either side (Figure 1.9)46. The regions around the 
cleavage site, as well as between the cleavage site and the C-terminus, are poorly 
packed46. Multiple side chain conformations are visible for cleavage site residues Met1606 
and Leu1603, whereas disordered side chains are not seen in similar buried positions in the 
crystal structure of the VWF A1 and A3 domains (Figure 1.8)44,45,46. Cys1669 and Cys1670 
are linked in a vicinal disulfide bond at the C-terminus of the A2 domain (Figure 1.9)46. 
Strikingly, all A2 interactions occur in this C-terminal portion, and this region is bounded 
by the β4-strand and the α6-helix, which contain the key recognition sites for 
ADAMTS13, which have been defined using peptide substrates60,69,70,71. Deletion of 
Cys1669-Cys1670 markedly enhances cleavage of VWF multimers by ADAMTS1372. 
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Figure 1.11.  Crystal structure of the ADAMTS13-DTCS fragment. Adapted from Akiyama 
et. al.68 Panel A shows a schematic representation of the domain structures of full-length 
ADAMTS13 and ADAMTS13-DTCS. Panels B and C show the ribbon structure of ADAMTS13-
DTCS (form 1) and ADAMTS13-DTCS (form 2), respectively. 
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1.4 ADAMTS13 Pathophysiology 
1.4.1 Deficiency of ADAMTS13 causes Thrombotic Thrombocytopenic Purpura 
Thrombotic Thrombocytopenic Purpura (TTP), first described by Eli Moschcowitz in 
192473, is a potentially fatal syndrome. The clinical manifestations of this disease are 
thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms and 
signs, and various degrees of renal functional abnormalities74. TTP is caused by the 
inability to cleave VWF due to hereditary8,75,76,77 or acquired deficiency13,14,55 of plasma 
ADAMTS13 activity.  
Approximately 5% of all TTP cases are caused by hereditary mutations of 
ADAMTS138. The mutations are present throughout the gene, causing changes in 
amino acid composition, truncation of protein and impaired secretion78,79,80. Most cases 
of adult TTP are caused by autoantibodies against ADAMTS13. In the earliest reports, 
inhibitors of ADAMTS13 were found in 65% to 96% of patients with acquired 
(idiopathic) TTP with severe deficiency (less than 5∼10% of normal activity)74. In later 
prospective studies, a lower prevalence of anti-ADAMTS13 autoantibodies (31-44%) 
was reported (Table 1.2)81,82. Assessment of binding activity by ELISA has indicated 
that autoantibodies can be found in almost all patients with acquired (idiopathic) TTP 
who exhibit a severe deficiency of plasma ADAMTS13 activity83. Autoantibodies 
against ADAMTS13 were also detected in six of seven patients with ticlopidine-
associated TTP, and in two patients with clopidogrel-induced TTP84,85. What triggers 
autoantibody formation is still not known.  
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Table 1.2. Prevalence of autoantibodies against ADAMTS13 in 
patients with idiopathic TTP  
Authors, year81,82,83,84,85 Number of positive/investigated % positive 
Furlan et. al., 1998 20/24 83% 
Tsai et. al., 1998 26/39 67% 
Tsai et. al., 2001 31/41 76% 
Veyradier et. al., 2001 30/59 51% 
Rich et. al., 2002 26/29 90% 
Study et. al., 2003 31/50 62% 
Coppo et. al., 2004 17/31 55% 
Zheng et. al., 2004 7/20 44% 
 
1.4.2 Autoantibodies in the pathogenesis of Thrombotic Thrombocytopenic Purpura 
Despite of the importance of autoantibodies in pathogenesis of TTP, and its presence 
correlates with more relapsing disease and poorer prognosis than its absence82,86,87, the 
binding epitopes and functional consequences of many autoantibodies against various 
domains of ADAMTS13 remain poorly understood. A limited number of published 
studies demonstrated that the major binding epitopes of autoantibodies are localized to 
Cys and Spa82,83,86,87,88.  
Using recombinant ADAMTS13 and variants expressed in mammalian cells, our lab 
also showed that approximately 30-45% of TTP patients harbored antoantibodies 
recognizing the middle TSP1 2-8 repeats and distal CUB domains82. Cys and Spa have 
been shown to play a critical role in the recognition and cleavage of a peptidyl substrate 
(VWF73), denatured VWF, and VWF under shear stress59,60,61. These domains have also 
been shown to be important for the in vivo function of ADAMTS1365. However, the 
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roles of the middle and distal C-terminal domains remain unclear. Understanding the 
biological and pathological significance of these autoantibodies against the middle and 
distal C-terminal domains will provide novel insight into the pathogenesis of TTP.  
 
1.6 Specific Aims of the Thesis Research 
The long-term goal is to understand of the biology of VWF processing by ADAMTS13, 
and thereby the pathophysiology of thrombotic complications. ADAMTS13 cleaves 
native VWF relatively poorly, and its preference for cleavage of the larger multimers is 
considered to lie in their greater susceptibility to deformation under shear stress or under 
flow. The specific hypothesis behind this thesis research is that physiological cofactors 
form ternary complexes with VWF and ADAMTS13 and, in addition to shear stress, 
cause the required conformational change of VWF to accelerate proteolytic processing by 
ADAMTS13 and that the ability of ADAMTS13 to recognize and cleave VWF is 
governed by exosite interactions with VWF.  
Chapter 2 demonstrates that both FVIII and platelets can serve as cofactors for 
enhancing VWF proteolysis by ADAMTS13 by synergistically altering VWF 
conformation under shear stress. This rate-enhancing effect of both platelets and FVIII on 
ADAMTS13-mediated VWF proteolysis depends on the specific high affinity 
interactions between FVIII/platelets and VWF. 
Chapter 3 demonstrates that a naturally-occurring type 2N VWF variant that exhibits 
significantly reduced FVIII binding is compromised in proteolytic cleavage by ADAMTS13 
in the presence of FVIII, proportional to the defects of their FVIII binding. These results 
demonstrate the role the VWF propeptide and FVIII-binding site (D’D3 domains) in 
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regulating VWF proteolysis by ADAMTS13 and suggest an evolutionary advantage by 
limiting VWF proteolysis in cases of VWD. Currently, the developed assays for detecting 
ADAMTS13 cleavage of VWF require simultaneous cleavage of scissile bonds in 
adjacent subunits, greatly underestimating the true catalytic efficiency of ADAMTS13. 
Thus, Chapter 3 also describes a novel ELISA-based assay detects the N-terminal 
peptide (i.e. EQAPNVY) resulting from cleavage after the Tyr residue occurring 
anywhere along a VWF multimer, which dramatically increases the sensitivity of the 
ADAMTS13-mediated VWF cleavage assay. 
Chapter 4 examines the specific exosite interactions that govern binding to the Spa 
domain of ADAMTS13 and their effects on VWF cleavage and binding of inhibitory 
anti-ADAMTS13 antibodies. This work, as part of two published papers, was primarily 
done by others in the lab. Here, I describe my contributions to the project. Following is a 
description of the crystallization, screening, data collection, and structure determination 
for an autolysis product of ADAMTS13, the ADAMTS13-CS fragment. 
Chapter 5 explores the in vivo function of ADAMTS13, specifically the composition of 
Adamts13-/- mice thrombi, as well as the differential composition at the head and tail of 
the thrombus. We determined that infusion of recombinant FL-ADAMTS13 or a 
truncated ADAMTS13 variant into Adamts13-/- mice restored the kinetics of platelet/red 
blood cell accumulation and fibrin formation to those observed in wild-type mice. Our 
findings, revealing the apparent difference in thrombus composition, provide novel 
insight into the mechanism of ADAMTS13 function in vivo. 
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Chapter 6 concludes with a discussion regarding the implications of the results described 
in the preceding chapters as well as a comprehensive analysis of future works in the field 
of cofactor- and exosite interaction-mediated VWF proteolysis by ADAMTS13. 
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2.1 Overview 
Previous studies have demonstrated that factor VIII (FVIII) or platelets alone increase 
cleavage of von Willebrand factor (VWF) by ADAMTS13 under mechanically-induced 
shear stresses. We show in this study that the combination of FVIII and platelets at 
physiological concentrations is more effective than either one alone. In the absence of 
FVIII, lyophilized platelets increase the formation of cleavage product by 2-3 fold. 
However, in the presence of physiological concentrations of FVIII (1 nM), the formation 
of the VWF cleavage product dramatically increases as a function of increasing platelets 
with a maximal rate enhancement of ∼8 fold. Conversely, in the presence of a 
physiological concentration of lyophilized platelets (150×103/µl), the half maximal 
concentration of FVIII required to accelerate VWF proteolysis by ADAMTS13 reduces 
by ∼10 fold (to ~0.3 nM) compared with that in the absence of platelets (∼3.0 nM). 
Further studies using a FVIII derivative that lacks an acidic region (a3), an anti-platelet 
glycoprotein 1bα (GP1bα) IgG, and a purified recombinant VWF-A1 domain or GP1bα-
stripped platelets demonstrate that the synergistic rate enhancing effect of FVIII and 
platelets depends on their specific binding interactions with VWF. Our findings suggest 
that FVIII and platelets are cofactors that regulate proteolysis of multimeric VWF by 
ADAMTS13 under physiological conditions. 
2.2 Introduction 
Proteolytic processing of UL-VWF by ADAMTS13 appears to occur at least at two 
different sites: one is on the endothelial cells where UL-VWF is newly released from 
Weibel-Palade bodies upon stimulation1,2 and the other may occur in solution (or 
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blood)3,4. The cleavage of the cell membrane-anchored UL-VWF by ADAMTS13 occurs 
very rapidly and requires low1,2,5 or almost no shear stress6,7. However, the cleavage of 
UL-VWF on the endothelial cell membrane does not appear to be sufficient to reduce the 
VWF multimer sizes that have been observed in plasma. The soluble VWF cleaved from 
the endothelial cell membrane by ADAMTS13 remains ultra large in size and the 
multimer distribution is not different from that released from Weibel-Palade bodies upon 
histamine stimulation6. Thus, further proteolytic cleavage of the released or soluble UL-
VWF in circulation may be necessary to reduce VWF multimer sizes consistent with 
normal distribution. This is likely accomplished in small arterioles and capillaries, where 
high fluid shear stress is present. Patients with aortic stenosis, which generates high flow 
shear stress in circulation, do exhibit increased VWF proteolysis and reduced VWF 
multimer size as compared with healthy individuals8,9, suggesting that increased VWF 
proteolysis is correlated with increased fluid shear stress in vivo. However, under in vitro 
assay conditions, fluid shear stress alone10,11 has only a modest effect on proteolytic 
cleavage of soluble multimeric VWF by ADAMTS13, suggesting that other proteins or 
non-protein cofactors or cellular components may be required for efficient proteolytic 
processing of soluble multimeric VWF by ADAMTS13.    
Shim et al12 and we10 have demonstrated that lyophilized platelets  or coagulation factor 
VIII (FVIII) alone at physiological concentrations can increase the proteolytic cleavage 
of VWF by ADAMTS13 by ∼2-3 fold under mechanically-induced fluid shear 
stresses10,12. In this study, we show that the combination of the two (FVIII and platelets) 
at physiological concentrations synergistically accelerate the proteolytic cleavage of 
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VWF by ADAMTS13 under similar conditions. This rate-enhancing effect of both 
platelets and FVIII on ADAMTS13-mediated VWF proteolysis depends on the specific 
high affinity interactions between FVIII/platelets and VWF. These findings suggest that 
binding of the platelet GP1bα receptor and FVIII to the specific regions of VWF may 
accelerate the conformational alterations under fluid shear stress, thereby allowing 
ADAMTS13 to access the binding site and cleavage bond. Our study provides a novel 
insight into how proteolytic cleavage of soluble multimeric VWF by ADAMTS13 may 
be regulated under physiologically relevant conditions. 
 
2.3 Materials and Methods 
2.3.1 Preparation of plasma and recombinant proteins 
Multimeric VWF was prepared from plasma using the method developed in the 
laboratory. All studies involving human materials were approved by the Institutional 
Review Board, the Children’s Hospital of Philadelphia. Briefly, citrated human plasma 
(2.5 liters) yet to be discarded in the Apheresis Unit, the University of Pennsylvania 
Hospital was frozen at -80 ºC and thawed at 4 ºC overnight. The thawed plasma was 
centrifuged at 4 ºC for 30 min at 15,000g. The supernatant was decanted and 
cryoprecipitate was dissolved with ~80 ml of PBS in the presence of 20 mM EDTA, 1 
mM PMSF, and 5 mM benzamidine at 37 ºC. After removal of the insoluble materials by 
centrifugation, the supernatant was further precipitated with 10% polyethylene glycol 
(PEG) 8,000 to reduce the volume. The precipitate was then re-dissolved with 10 ml 
PBS. Only 5 ml of clear supernatant (~1% of the column volume) was loaded onto a 
Sephacryl-300 gel filtration column (2.5 cm x100 cm, ~490 ml) (GE Healthcare, 
41 
 
Piscataway, NJ). The purity of VWF was determined by 8% SDS-polyacrylamide gel and 
Coomassie blue staining. The multimer distribution was determined by 1% mini-agarose 
gel electrophoresis and Western blotting as described previously10,13. The amount of 
purified VWF was determined by absorbance at 280 nm corrected by absorbance at 320 
nm (1 corrected absorbance at 280 nm equals to ~1 mg/ml). The purified plasma VWF is 
free of detectable FVIII, assessed by an enzyme-linked immunoassay established in the 
laboratory. Recombinant ADAMTS13 was expressed in stably transfected HEK293 cells 
and purified according to the protocol described previously11,14. The contaminated 
proteins were removed by gel filtration on a Superose-6 column (GE Healthcare, 
Piscataway, NJ) with 20 mM HEPES, pH 7.5, 150 mM NaCl, and 5 mM CaCl2 (Figure 
2.1). The amount of the purified proteins was determined by absorbance at 280 nm 
(corrected with light scattering at 320 nm) (1 corrected absorbance at 280 nm equals to 
~0.68 mg/ml) as described previously11,14. Recombinant human FVIII and FVIII 
derivative (FVIII-2RKR) were prepared as previously described10. The final products 
were exchanged into 20 mM HEPES, 0.15 M NaCl, and 5 mM CaCl2, pH 7.5, and stored 
at -80 °C.  
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Figure 2.1. Initial purification of ADAMTS13-V5His. Recombinant ADAMTS13 was 
expressed in stably transfected HEK293 cells and purified. The contaminated proteins were 
removed by gel filtration on a Superose-6 column (GE Healthcare, Piscataway, NJ) with 20 mM 
HEPES, pH 7.5, 150 mM NaCl, and 5 mM CaCl2 (Panel A). The amount of the purified proteins 
was determined by absorbance at 280 nm (corrected with light scattering at 320 nm) (1 corrected 
absorbance at 280 nm equals to ~0.68 mg/ml). Coomassie blue gel showing the fractions from the 
“B” and “C” peaks (Panel B). The fractions in the “B” peaks comprised the collected full-length 
ADAMTS13 (arrowhead). 
 
2.3.2 Preparation of fresh and lyophilized human platelets 
Whole blood (10 ml) from a healthy volunteer was drawn to a blue top tube containing 
3.8% sodium citrate and 1 µg/ml prostaglandin E1.  Platelet-rich plasma (PRP) was 
prepared by centrifugation of the anti-coagulated whole blood at 1,000 rpm for 10 
minutes. The PRP was then loaded onto a Sepharose-2B column (GE Healthcare, 
Piscataway, NJ) pre-equilibrated with Modified Tyrode’s buffer (20 mM HEPES pH 7.4, 
137 mM NaCl, 5.6 mM Glucose, 1 g/l BSA, 1 mM MgCl2, 2.7 mM KCl, 3.3 mM 
NaH2PO4). The fractions containing platelets were pooled and the platelet concentration 
was determined by manual counting using a hemacytometer under a light microscope. 
Formalin-fixed and lyophilized human platelets were purchased from Helena 
Laboratories, Beaumont, TX. The platelets were reconstituted with 10 ml of 20 mM Tris-
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HCl, pH 7.4, and 100 mM NaCl, and centrifuged at 10,000 rpm for 5 minutes. The pellets 
were re-suspended in the same buffer to a platelet concentration of 20x106/µl, determined 
by counting in the hemacytometer.  
 
2.3.3 Removal of GP1bα receptor from fresh platelets by O-sialoglycoprotein 
endopeptidase 
Freshly isolated human platelets (3x109/µl) were treated without or with various 
concentrations (0-400 µg/ml) of O-sialoglycoprotein endopeptidase (OSE) isolated from 
Pasteurella haemolytica15,16,17 (Cedarlane Laboratories, Burlington, NC) at 25°C for 4 
hours in Modified Tyrode’s buffer. OSE specifically cleaves proteins containing O-linked 
glycans, but spares N-linked glycoproteins or unglycosylated proteins18,19,20. This 
metallo-endoprotease has been reported to specifically cleave the 25-kDa N-terminal 
fragment of platelet GPIbα, which is heavily O-glycosylated, while not affecting other 
receptors such as GPIIb-IIIa21. The enzyme-digested fresh platelets were washed with 
Modified Tyrode’s buffer to remove the excessive protease, soluble GP1b and VWF prior 
to addition into the reactions.   
 
2.3.4 Ristocetin-induced platelet agglutination (RIPA) assay 
Freshly-isolated platelets that were treated with the Modified Tyrode’s buffer alone or 
various concentrations of OSE (0, 25, 50, 100, 200, and 400 µg/ml) in Modified Tyrode’s 
buffer for 4 hours were mixed with purified plasma VWF (15 µg/ml, final concentration), 
and ristocetin (1 mg/ml) (Helena Laboratories, Beaumont, TX) in a glass tube with 
stirring at 1,100 rpm. The light transmission was recorded simultaneously in all the 
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channels for 4 minutes at 37°C with a PAP-8E aggregation module (Bio/Data 
Corporation, Horsham, PA). The relative difference in light transmission before and after 
addition of ristocetin was used to determine the percentage of platelet agglutination. The 
light transmission prior to addition of ristocetin was defined as 0%, whereas the maximal 
light transmission was 100%.  
 
2.3.5 Cleavage of multimeric VWF by ADAMTS13 under fluid shear stress 
Purified plasma VWF (37.5 µg/ml or 150 nM of VWF subunits) was incubated with 
recombinant ADAMTS13 (25 nM) in the presence or absence of various other 
components (such as FVIII, FVIII-2RKR and platelets) in 20 mM HEPES, pH 7.5 
containing 1 mg/ml BSA, 150 mM NaCl and 5 mM CaCl2 in a 0.2 ml thin-walled PCR 
tube with dome caps (total volume 20 µl) for 10 min. The reaction mixtures were then 
subjected to mixing in a 96-well Eppendorf MixMate vortexer (Fisher-Thermo Scientific, 
Pittsburg, PA) at rotation rate of 2,500 rpm for 10 min. The reaction mixtures were then 
denatured without reducing agents at 100 ºC for 5 min with a sample buffer [62.5 mM 
Tris-HCl, pH 6.8, 25% glycerol, 2% sodium dodecyl sulfate (SDS), and 0.01% 
bromophenol blue] for the SDS-polyacrylamide gel or at 60 ºC for 20 min with a sample 
buffer (70 mM Tris-HCl, pH 6.5 containing 2.4% SDS, 4% urea, and 4 mM EDTA) for 
the agarose gel. The denatured VWF substrate was fractionated either in a 5% Tris-
glycine SDS polyacrylamide gel at 25 ºC, 120V for 150 min or in a 1% agarose gel at 4 
ºC, 15 mA for 100 min in a Mini-protein III gel cassette (Bio-Rad, Hercules, CA). The 
proteins were then transferred onto a nitrocellulose membrane (Millipore, Billerica, MA) 
at 100 mA for 60 min from the SDS polyacrylamide gel and at 15V for 30 min from the 
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agarose gel, respectively. The proteolytic cleavage products of VWF were detected by 
rabbit anti-VWF IgG (1:5,000) (Dako, Carpinteria, CA) and IRDye 800CW-labeled goat 
anti-rabbit IgG (1:12,500-20,000) (LI-COR Bioscience, Lincoln, Nebraska) in TBS 
containing 1% casein and 0.05% Tween 20. The fluorescent signals were collected by an 
Odyssey infrared imaging system (LI-COR Bioscience, Lincoln, Nebraska) (22). The 
cleavage products were quantified by NIH ImageJ software after the fluorescent 
intensities were converted into the gray image signals. 
 
2.4 Results 
2.4.1 Factor VIII and platelets synergistically increase cleavage of VWF by ADAMTS13 
under fluid shear stress 
Previous studies have shown that FVIII10 or platelets12 separately increase proteolytic 
cleavage of VWF by ADAMTS13 under mechanically-induced fluid shear stress. FVIII 
and platelets both bind VWF with high affinity at two distinct regions, i.e. D’D3 domain 
and A1 domain, respectively22. We sought to determine whether binding of FVIII and 
platelets to VWF could synergistically enhance proteolytic cleavage of VWF by 
ADAMTS13 under fluid shear stress conditions. In these experiments, purified plasma-
derived VWF (∼150 nM or 37.5 µg/ml) was incubated with purified recombinant 
ADAMTS13 (∼25 nM) in the absence or in the presence of a fixed concentration of 
purified recombinant FVIII (1 nM) or lyophilized platelets (150x103/µl) or both at 25 ºC 
for 10 min in assay buffer (20 mM HEPES pH 7.5, 1 mg/ml BSA, 150 mM NaCl and 5 
mM CaCl2) under constant vortexing (2,500 rpm) in a PCR tube mixer.  
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Under the current conditions, the control reactions in the presence of EDTA (10 mM) or 
in the absence of ADAMTS13 or without vortexing exhibited no detectable cleavage 
product by Western blotting (Figure 2.2). The proteolytic cleavage of VWF by 
ADAMTS13 in the presence of 1 nM of FVIII or 150-600×103/µl of lyophilized platelets 
alone increased by 2-3 folds after 10 minutes of incubation on the PCR tube mixer (2,500 
rpm) (Figure 2.2). However, when both FVIII (1 nM) and lyophilized platelets 
(150×103/µl) were added into the reaction, more substantial increase in the formation of 
cleavage product was detected than in the presence of either FVIII or platelets alone 
(Figure 2.2). The amount of cleavage product formed when both FVIII and platelets were 
present was ∼8 fold (Figure 2.2), greater than the sum of the product generated in the 
presence of either FVIII or platelets alone, suggesting a synergistic effect of FVIII and 
platelets in enhancing VWF proteolysis by ADAMTS13 under fluid shear stress.  
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Figure 2.2. Factor VIII and platelets synergistically accelerate cleavage of VWF by 
ADAMTS13 under shear stress. Purified human plasma VWF (~150 nM) was incubated with 
recombinant ADAMTS13 (25 nM) in the absence (-) or the presence (+) of recombinant FVIII (1 
nM) and/or lyophilized platelets (150×103/µL) for 10 min under constant mixing on the MixMate 
vortexer at 2,500 rpm, which generates fluid shear stress (~32 dyn/cm2). The proteolytic cleavage 
product (350 kDa) (arrowhead) was determined by Western blotting with rabbit anti-VWF IgG, 
followed by IRdye 800-labeled goat anti-rabbit IgG. The image was obtained by an Odyssey 
imaging detection system. Negative controls including the omission of ADAMTS13, FVIII or 
platelet or addition of EDTA (10 mM) showed no detectable cleavage product. 
 
 
Consistent with previously reported results, in the presence of increasing concentrations 
of platelets, VWF cleavage was increased (Figure 2.3). Addition of 1 nM FVIII to the 
reaction shifted the curve to lower concentrations of platelets (Figure 2.3), indicating that 
FVIII and platelets can synergistically increase VWF proteolysis by ADAMTS13. 
Conversely, in the absence of platelets FVIII alone increased the formation of cleavage 
product in a concentration dependent manner (Figure 2.4). However, in the presence of 
physiological concentration of platelets (~150x103/µl), FVIII more dramatically 
increased the formation of the proteolytic cleavage product, which shifted the FVIII dose 
response curve to the left. Therefore, the concentration of FVIII required to achieve the 
half maximal cleavage of VWF by ADAMTS13 (C50) was reduced by 10-fold (from 3.0 
nM in the absence of platelets to 0.3 nM in the presence of platelets) (Figure 2.4), which 
falls into the physiological range of human plasma FVIII concentrations.   
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Figure 2.3. Cleavage of VWF by ADAMTS13 in the presence of fixed concentration of 
FVIII and various concentrations of platelets under shear stress. Purified human plasma 
VWF (~150 nM) was incubated with recombinant ADAMTS13 (25 nM) in the absence (-FVIII) 
or the presence (+FVIII), but with increasing concentrations of lyophilized platelets (0-
600x103/µl) at 25 ºC for 10 min under constant mixing at 2,500 rpm on the MixMate PCR mixer. 
The proteolytic cleavage product of VWF (350 kDa) (arrowhead) was determined by Western 
blotting. The 350 kDa band (Panel A, arrowhead) was quantified by densitometry using Image J 
software and the fold of increase compared with that in the absence of platelet and FVIII in Lane 
1 was plotted against platelet concentrations (Panel B). The results are the mean ± standard error 
from three independent experiments. 
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Figure 2.4. Cleavage of VWF by ADAMTS13 in the presence of fixed concentration of 
platelets and various concentrations of FVIII under shear stress. Purified human plasma 
VWF (~150 nM) was incubated with recombinant ADAMTS13 (25 nM) in the absence (-) and 
the presence (+) of lyophilized platelets (150x103/µL) and various concentrations of recombinant 
FVIII (0, 0.5, 1, 2.5, 5 and 10 nM) for 10 min under constant mixing at 2,500 rpm on the 
MixMate PCR mixer. The proteolytic cleavage product (350 kDa) (Panel A, arrowhead) was 
detected by Western blotting as described.  The 350 kDa-band of proteolytic cleavage product in 
the absence (-Plt) and in the presence of platelet (+Plt) was plotted against the concentrations of 
FVIII (Panel B). The data (fold of increase) represent the mean ± standard error from three 
independent experiments. 
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2.4.2 Binding of FVIII to VWF is required for their synergistic effect on VWF proteolysis 
by ADAMTS13 under shear stress 
FVIII binds VWF with high affinity (KD, 0.3∼0.5 nM) through its interaction with the 
D’D3 domain of VWF22. This high affinity binding appears to be necessary for the 
enhancing effect of FVIII on VWF proteolysis by ADAMTS13 under shear stress10. To 
determine whether the binding of FVIII to VWF is also required for synergistic rate 
enhancement with platelets, we incubated plasma VWF (150 nM) with ADAMTS13 (25 
nM) in the presence of 1 nM of a B-domain less FVIII lacking the acidic (a3) region (i.e. 
FVIII-2RKR) that is responsible for high affinity binding to VWF22 and various 
concentrations of lyophilized platelets (0-600x103/µl) under the same conditions. We 
showed that in the presence of FVIII-2RKR (instead of wild type FVIII), platelets (up to 
600x103/µl) increased the formation of proteolytic cleavage of VWF by ADAMTS13 by 
∼2-3 fold (Figure 2.5), similar to that observed in the absence of FVIII. These results 
suggest that the high-affinity binding interaction between FVIII and VWF is required for 
the synergistic effect of FVIII with platelets accelerating VWF proteolysis by 
ADAMTS13 under fluid shear stress.  
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Figure 2.5. Cleavage of VWF by ADAMTS13 in the presence of fixed concentration of 
FVIII-2RKR and various concentrations of platelets. Purified human plasma VWF (~150 nM) 
was incubated with ADAMTS13 (25 nM) in the presence of 1 nM of recombinant wild-type 
FVIII or a B-domain-deleted variant lacking the acidic region (a3) (FVIII-2RKR) and increasing 
concentrations of lyophilized platelets (0-600x103/µl) for 10 min at 25 ºC under constant mixing 
at 2,500 rpm on the MixMate PCR mixer. The proteolytic cleavage product (350 kDa) (Panel A, 
arrowhead) was determined by Western blotting (Panel B). The quantification of 350 kDa band 
(fold Increase) was determined by densitometry. Results represent the mean ± standard error from 
three independent experiments.  
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2.4.3 Binding of platelet receptor GP1bα to VWF is also required for the synergistic 
effect of platelets with FVIII on VWF proteolysis by ADAMTS13 under shear stress 
Platelets bind VWF with high affinity through their interactions of the surface receptor 
GP1bα with the A1 domain of VWF22. To determine whether binding of platelet receptor 
GP1bα to the VWF-A1 domain may be required for the synergistic effect of platelets 
with FVIII on VWF proteolysis by ADAMTS13, we incubated VWF and ADAMTS13 in 
the absence and presence of increasing concentrations of monoclonal anti-GP1bα IgG 
(6D1) (Figure 2.6A and C), provided by Dr. Barry Coller at Rockefeller University, New 
York, NY23 or purified A1 domain (Figure 2.5B and D), provided by Dr. Miguel Cruz at 
Baylor College of Medicine, Houston, TX, under constant vortexing at 2,500 rpm for 10 
min. We showed that an addition of purified A1 domain or 6D1 to the reaction 
dramatically inhibited the formation of the proteolytic cleavage product in a 
concentration-dependent manner. 6D1 at a concentration of 0.8 µM (Figure 2.6A and C) 
or VWF-A1 domain at a concentration of 0.75 µM (Figure 2.6B) almost completely 
blocked proteolytic cleavage of VWF by ADAMTS13 despite of the presence of 1 nM 
FVIII, suggesting that the interaction between VWF-A1 and GP1bα may be more 
important in regulating cleavage of the VWF-A2 domain by ADAMTS13.  
Furthermore, freshly isolated platelets pre-treated with 200 µg/ml of O-sialoglycoprotein 
endopeptidase (OSE) for 4 hours, which selectively removed a 25-kDa N-terminal 
fragment of the platelet surface receptor GP1bα, but spared receptor GPIIb-IIIa, exhibited 
a dramatically reduced rate-enhancing effect on the VWF proteolysis by ADAMTS13 in 
the presence of FVIII (1 nM) (Figure 2.6A and B). These results suggest that the 
synergistic rate-enhancing activity of platelets with FVIII depends on the specific VWF-
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A1 and GP1bα interaction. As a control, fresh platelets treated with a buffer alone 
worked as well as or appeared to be better than the lyophilized platelets in accelerating 
VWF proteolysis by ADAMTS13 under fluid shear stress (Figure 2.6A and B), consistent 
with that previously reported12. The more pronounced rate enhancing effect of fresh 
platelets than lyophilized platelets may be partially attributed to the platelet-bound VWF, 
which increased VWF substrate concentration in the reactions as demonstrated in the 
multimer analysis (Figure 2.6A). Such a result was not observed using a 5% SDS-
polyacrylamide gel by Shim et al12, as most of the undigested VWF could not get into the 
gel for accurate assessment of VWF antigen.  Treatment of freshly isolated platelets with 
OSE removed platelet-bound VWF as a result of the removal of GP1bα receptor on the 
platelet surface (Figure 2.6A).   
To assess whether the GP1bα receptor was removed or not, we tested the ability of these 
treated platelets to agglutinate upon induction with ristocetin. As shown in Figure 2.5C, 
OSE treatment dramatically reduced ristocetin-induced platelet agglutination in a 
concentration- dependent manner. In the presence of 50 µg/ml of OSE, the ristocetin-
induced platelet agglutination was almost completely inhibited (Figure 2.6C), whereas 
the control platelets treated for 4 hours at 37 ºC with Modified Tyrode’s buffer 
aggregated normally (Figure 2.6C). Together, our data support a hypothesis that the 
specific interactions between GP1bα receptor and VWF-A1 domain, but not the 
membrane scaffold interactions, may be necessary for the synergistic rate enhancing 
effect of platelets with FVIII on proteolytic cleavage of VWF by ADAMTS13 under 
physiologically relevant fluid shear stresses.   
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Figure 2.6. Disruption of VWF-platelet interactions inhibits cleavage of VWF by 
ADAMTS13 under shear stress. Purified plasma VWF (150 nM) was incubated with 
ADAMTS13 (25 nM), lyophilized platelets (150x103/µl), and FVIII (1 nM) in the absence or 
presence of increasing concentrations of 6D1 anti-GP1b IgG (panel A) or purified A1 domain 
(Panel B). In addition, purified VWF (150 nM) was incubated with ADAMTS13 (25 nM), and 
FVIII (1 nM) in the absence (Panel C & D, Lane 1) or the presence of various concentrations of 
fresh platelets (150x103/µl) that were pre-treated without (Panel C) or with 200 µg/ml of O-
sialoglycoprotein endopeptidase (Panel D) for 4 hours and washed. The removal of GP1b 
receptor from the platelet surface was assessed by ristocetin-induced light scattering platelet 
agglutination assay (Panel E). 
 
2.4.4 Assessing the amount of fluid shear stress generated in the assay system 
The described in vitro system, which contains only plasma VWF, ADAMTS13, FVIII, 
platelets, and a physiologic buffer, is not subject to the changes in fluid viscosity that 
would be observed in blood. The system could, thus, be considered a Newtonian system 
in which the relationship between shear stress and shear rate is linear. Using a cone-plate 
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viscometer we showed that water (Figure 2.7A) and a reaction system (Figure 2.7B) 
containing purified plasma VWF (~150 nM), recombinant ADAMTS13 (25 nM), 
recombinant FVIII (2 nM) and lyophilized platelets (150×103/µl) exhibited a Newtonian 
behavior. This indicates that the observed increase in cleavage product can be directly 
correlated to the increase in fluid shear stress generated in the system, but not to the 
changes in the fluid viscosity of the reaction mixture.  
To assess the wall shear stress generated in our vortex assay reactions, we compared the 
fold increase of the VWF cleavage product in the presence and in the absence of FVIII 
and platelets on a cone-plate viscometer with that on two different vortexers. We found 
that the fold increase in the formation of VWF cleavage product dramatically increased 
as a function of increasing fluid shear stress on the cone-plate viscometer in the presence 
of physiological concentrations of FVIII and platelets, but modestly increased in the 
absence of added FVIII and platelets (Figure 2.7C). Curve fitting of the data obtained 
from 3 independent experiments revealed a linear relationship between the shear stress 
and the fold enhancement in the VWF cleavage (Figure 2.7D). Using this standard 
function, the fluid shear stress generated in the MixMate PCR tube mixer and mini-
vortexer was estimated to be ~32 dynes/cm2 and ~75 dynes/cm2, respectively (Figure 
2.7C and D). The difference in fluid shear stress generated among the PCR tube mixer, 
the mini-vortexer and cone plate viscometer may offer some explanation for the 
formation of various amount of proteolytic cleavage product in different assays. 
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Figure 2.7. Assessing the fluid shear stress generated by various vortexing assays. Panels A 
and B demonstrate the linear relationships between the averaged fluid shear stress and shear rate 
when water and a reaction mixture containing VWF (150 nM), ADAMTS13 (25 nM), FVIII (2 
nM) and lyophilized platelets (150x103/µl) was placed on the cone-plate viscometer, respectively. 
Panel C shows a shear-dependent increase in proteolytic cleavage product in the absence and the 
presence of FVIII/platelets. In this experiment, purified plasma VWF (~150 nM) was incubated 
with recombinant ADAMTS13 (25 nM) in the absence (-) or the presence (+) of recombinant 
FVIII (2 nM) and lyophilized platelets (150×103/µL) for 10 min under increasing shear rates on a 
cone-plate viscometer (HAAKE RotoVisco1) (Lanes 1-8) or Mini-vortexer (Fisher Scientific) 
(Lanes 9-10) or MixMate PCR mixer (Eppendorf) (Lanes 11-12) for 10 min at rotation rate of 
2,500 rpm.  The proteolytic cleavage product (350 kDa) (arrowhead) was determined by Western 
blotting. Panel D demonstrates the ratio of the cleavage product (mean ± SD) (y-axis) in the 
presence of FVIII/platelets to that in the absence of FVIII/platelets obtained from the cone-plate 
viscometer experiments (n=3) plotted against fluid shear stress (x-axis). As seen, the mini-
vortexer and the MixMate PCR mixer generate ~75 dynes/cm2 and 32 dynes/cm2 of shear stress, 
respectively. 
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2.5 Chapter Discussion 
This study demonstrates the synergistic effect of FVIII and platelets, accelerating 
proteolytic cleavage of soluble VWF by ADAMTS13 under mechanically-induced fluid 
shear stress. Unlike cleavage of newly released and membrane-anchored UL-VWF on 
stimulated endothelial cells which requires little or no shear stress1,2,5 or cofactors6, the 
proteolytic cleavage of soluble VWF by ADAMTS13 requires drastic manipulations, 
such as denaturation of VWF substrate with 1.5 M urea/guanidine14.24 or exposure of 
soluble VWF to high fluid shear stress10,11.  
High fluid shear stress results in conformational changes of VWF multimers and opens 
up the binding sites and cleavage bond in the central A2 domain25,26,27 normally buried  in 
the hydrophobic core of the native VWF-A2 domain41. However, in a diluted 
proteinaceous solution, the shear stress that an individual VWF molecule experiences 
may be quite small relative to the shear stress that has been applied to the reactions in our 
current assay system. Under such conditions, little or no detectable cleavage product was 
formed when no FVIII or platelets was added (Figures 2.2-2.4). Addition of FVIII or 
platelets to VWF alone can increase the formation of cleavage product (350 kDa) 
(Figures 2.2-2.4), suggesting that binding of FVIII or platelets to VWF may facilitate the 
deformation of VWF substrate by altering the domain-domain interactions among the 
various VWF subunits. This global conformational change appears to be sufficient to 
increase VWF proteolysis.  
There appear to be some differences in the fold enhancement by either FVIII or platelets 
on ADAMTS13-mediated VWF proteolysis between this report and those previously 
published10,12. These differences may result from the amount of shear stress applied and 
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the concentrations of VWF and ADAMTS13 used in the different assays. As shown in 
Figure 2.7, vortexing at the rotation rate of 2,500 rpm on a mini-vortexer generates ~75 
dynes/cm2 of fluid shear stress, whereas vortexing at the same rotation rate on a MixMate 
PCR mixer generates only ~32 dynes/cm2 of fluid shear stress.  
Further analyses demonstrate that FVIII and platelets act synergistically to accelerate 
VWF proteolysis by ADAMTS13 under shear stress (Figures 2.2-2.4). The enhancing 
effect of FVIII and platelets on VWF proteolysis appears to depend on the specific 
binding interactions between the light chain of FVIII and the VWF-D’D3 domain, and 
the interactions between platelet GP1bα receptor and the VWF-A1 domain. No 
synergistic effect is observed when the FVIII variant, FVIII-2RKR which fails to bind 
VWF, is added into the reactions (Figure 2.5). Furthermore, the synergistic effect of 
platelets with FVIII is dramatically inhibited by addition of an increasing concentration 
of 6D1 (Figure 2.6A and C) or purified VWF-A1 domain (Figure 2.6B and D), which 
disrupts the specific platelet-VWF interactions. The requirement of such specific VWF-
A1/GP1bα interactions for the synergistic rate enhancing effect of platelets with FVIII 
has been further supported by the lack of an enhancing effect of fresh platelets with FVIII 
after the N-terminal 25-kDa portion of the platelet GP1bα receptor has been removed by 
treatment with a metalloprotease (OSE) isolated from Pasteurella haemolytica, although 
the platelet-bound VWF may partially contribute to the increase in formation of the 
cleavage products (Figure 2.6).    
The binding of FVIII to the VWF-D’D3 domain may cause a large scale conformational 
change of VWF multimers, such as pulling away the D’D3 domain from its neighboring 
A1 or A2 domain in the presence of fluid shear stress. The binding of platelets or even 
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soluble GP1bα to the VWF-A1 domain may further alter the domain-domain interactions 
of multimeric VWF. This was shown to occur even after VWF or A1A2A3 or A1A2 has 
been pre-denatured under static conditions18.  
Moreover, the binding of two or more platelets on either side of the cleavage bond of 
VWF multimers may dramatically increase the peak force exerted on the central A2 
domain. For instance, in the presence of 20 dynes/cm2 shear force, the predicted peak 
force soluble VWF multimers experience ranges from 0.2 to 0.8 pN19 in the absence of 
platelets. The peak force increases to ~390 pN when two or more platelets are bound at 
either side of the scissile bond12,19. This is the amount of shear stress if applied directly to 
a VWF fragment such as the A1A2A3 or A2 domain in which both ends are attached to a 
solid surface27,28. However, this does not appear to be the case in our assay system as 
only a modest increase of VWF cleavage is observed with addition of physiological 
concentrations of lyophilized platelets alone (Figures 2.2-2.4). The combination of low 
occupancy of VWF by FVIII and platelets may increase the chances of being proteolyzed 
under fluid shear stress, which may be sufficient to eliminate circulating UL-VWF 
multimers under physiological conditions. However, our in vitro assay may 
underestimate the degree of VWF proteolysis since we rely on the appearance of the 350 
kDa product as a measure of proteolysis, which requires a simultaneous cleavage of two 
immediately adjacent Tyr-Met bonds. 
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2.7 Supplemental Information 
2.7.1 Towards a calculation of the average shear stress generated by the vortex method 
In vivo, because of the tendency of erythrocytes to deform and aggregate, blood is a fluid 
with non-Newtonian behavior. This indicates that blood viscosity varies with the force 
applied to it. Blood viscosity is dependent on shear rate, thus viscosity decreases when 
the shear rate increases. Shear rate is approximated by the velocity gradient and is 
primarily determined by the diameter of vessels. A high shear rate is present when flow is 
fast and the vessel diameter is small; a low shear rate is present when flow is slow and the 
vessel has a large diameter. The non-Newtonian behavior of blood is, thus, a result of the 
tendency of erythrocytes to aggregate at low shear rates.  
As described in the Results section, our in vitro system, which contains only plasma 
VWF, ADAMTS13, FVIII, platelets, and a physiologic buffer, is not subject to the 
changes in fluid viscosity that would be observed in blood and could, thus, be considered 
a Newtonian system (Figure 2.7A and B). 
Under this assumption, we may treat the 0.2 ml thin-walled PCR tube in a vortexer as a 
coaxial cylinder system with a small, but finite cylinder radius: 
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A                                  B 
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A = 3Ra
3
πRi
3
τ = ηγ A =
 
 
Figure S2.1. Calculation of an estimate of the average shear stress generated by the vortex 
method. Panel A demonstrates the dimensions of a coaxial cylinder system with a small, but 
finite cylinder radius. Panel B illustrates the formation of the coaxial cylinder system when shear 
stress (vortexing) is applied to a reaction in the tube. Panel C illustrates the approximate 
geometry of the liquid under vortexing conditions, while Panel D indicates the geometric 
correction that must be taken into account for the geometry indicated in Panel C. 
 
Given this setup, we can calculate that the average shear rate in the system (γ) is 
dependent on the angular velocity and the ratio of rotor radius to the container radius 
(along the boundary of the vessel): 
 
(Eq. 2.1) 
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Looking at this setup, the “rotor edges” are indicative of the liquid-air interface. Using 
the reaction volume (20 µl) and the tube capacity (200 µl), and given Equation 2.2, we 
can make a rough estimate of the average shear rate (γ): 
Ra − Ri ≈ 200 µm
δ=
Ra
Ri
=
0.2 mm
3.5 mm
+1= 1.06
M = 2δ
2
δ 2 −1




= 19.1
γ = 4.99 ×103  sec-1
 
n = 2500 rpm;  Ri = 3.5 mm; 
ρ(protein) ~ 1.35 kg/m3; ρ(solution) ~ 1.00 kg/m3 
From this estimate of the average shear rate (γ, Equation 2.6), we can calculate the 
average shear stress (τ) using dynamic viscosity (η) acquired by a cone-plate viscometer 
in previous experiments: 
η = 0.6 cP = 6 ×10−4  Pa ⋅s
 
τ = ηγ = 52.6 Pa
 
(Eq. 2.2) 
(Eq. 2.3) 
(Eq. 2.5) 
(Eq. 2.4) 
(Eq. 2.6) 
(Eq. 2.7) 
(Eq. 2.8) 
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Figure S2.2. Representative reading from the reaction system on the cone-plate viscometer. 
 
The geometry factor of the tube, which is found by simply using the approximate rotor 
geometry (Figure S2.1) is factored into the calculation from Equation 2.8 to give: 
A = 3Ra
3
πRi
3 =
3δ 3
π
= 0.96
τ = ηγ A = 2.88 Pa 
              = 28.8 dyne/cm2
 
Thus the calculated shear stress of ~30 dynes/cm2 is very close to the empirically-
determined shear stress of ~32 dynes/cm2. This provides further evidence that our 
Filename: C:\Program Files\RheoWin3\Data\Chris S\062408_5min.rwd
t_se g  ‚ [P a ]
Element def inition / Notes
ID 3: CR , 12000.00 1/s, t 300.00 s, #100, T 37.00 °C, IMG
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(Eq. 2.9) 
(Eq. 2.10) 
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assumption of a Newtonian system is reasonable, however it must be noted that all 
experiments done by the vortex method are confirmed by repeating the experiments on 
the cone-plate viscometer (HAAKE RotoVisco1, Thermo Fisher Scientific, Waltham, 
MA), a well-defined and well-characterized tool for generating fluid shear stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
CHAPTER 3: THE VWF D’D3 AND PROPEPTIDE DOMAINS PLAY A 
ROLE IN FACTOR VIII-MEDIATED ENHANCEMENT OF VWF 
PROTEOLYSIS BY ADAMTS13 
(Manuscript Title: Compromised Proteolytic Cleavage of Type 2N von Willebrand Factor 
Variants by ADAMTS13 in the Presence of Factor VIII) 
 
Christopher G. Skipwith
1,2
, Sandra L. Haberichter
3
, Ashley Gehrand
3
, and  
X. Long Zheng
1,2
 
From 
1
Biochemistry and Molecular Biophysics Graduate Group and 
2
Department of 
Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia and The 
University of Pennsylvania, Philadelphia Perelman School of Medicine, Philadelphia, 
PA; 
3
Blood Research Institute, Blood Center of Wisconsin, and Department of Pediatrics, 
Medical College of Wisconsin, Milwaukee, WI, USA. 
 
 
 
 
 
 
 
 
68 
 
3.1 Overview 
Proteolytic cleavage of von Willebrand factor (VWF) by ADAMTS13 is enhanced by 
clotting factor VIII (FVIII). In this study, we test the hypothesis that naturally occurring 
type 2N VWF variants that are defective in FVIII binding may be compromised in 
proteolytic cleavage by ADAMTS13 in the presence of FVIII. Recombinant type 2N 
VWF variants (H817Q, R854Q, R782W, R782W/H817Q, and HPP-VWF) were 
expressed in human embryonic kidney cells. Binding of FVIII and proteolytic cleavage of 
the 2N VWF variants were determined. We showed that most 2N VWF variants exhibited 
reduced proteolytic cleavage by ADAMTS13 in the presence of FVIII under fluid shear 
stress. The impairment of FVIII in accelerating the cleavage of the 2N VWF variants was 
proportional to the defects in their FVIII binding. In contrast, these variants, except for 
HPP-VWF, appeared to be cleaved normally in the presence of ristocetin and platelets, 
which modulate VWF proteolysis via the A1 domain. These results further support the 
critical role of the VWF D’D3 domain and the VWF propeptide in regulating VWF 
proteolysis by ADAMTS13 under physiologically relevant shear stress. Our findings 
suggest that the compromised cofactor-dependent proteolysis of the 2N VWF variants 
may be advantageous for mitigating bleeding phenotype in cases of von Willebrand 
disease. 
 
3.2 Introduction 
Type 2N VWD includes cases with defective binding of FVIII. Genetic analyses have 
shown that most 2N mutations are located in the exons 18-27, which affect the propeptide 
cleavage site and the D’-D3 domains that contain the FVIII binding sites9,10,11,12,13,14,15 . 
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Patients with 2N VWD resemble those with mild hemophilia A as  the result of variably 
reduced plasma FVIII activity, usually between 0.05 IU/ml and 0.40 IU/ml10,16. 
Symptoms in cases of type 2N VWD are known to be correlated with low plasma FVIII 
activity17 and the structure and functionality of plasma VWF multimers. For instance, 
plasma VWF multimers in type 2N patients may be normal, increased, smeared, or 
significantly reduced, depending on the type of VWF mutations16. A subset of 2N 
mutations (i.e. C788R/Y or C804F) in the D’ domain may affect intra-molecular disulfide 
bonds, thereby affecting the secondary structure, secretion, and multimerization of 
VWF18,19. However, most other 2N VWF mutations do not involve a cysteine residue (i.e. 
H817Q, R854Q, R782W, R782W/H817Q, and HPP-VWF identified through the Blood 
Center of Wisconsin). All patients with type 2N mutations exhibit a reduced FVIII 
binding affinity to various extents. 
We hypothesize that a type 2N VWF variant that exhibits significantly reduced FVIII 
binding may be compromised in proteolytic cleavage by ADAMTS13 in the presence of 
FVIII. This hypothesis stems from our previous observations, demonstrating the cofactor 
role of FVIII alone20 or with platelets21 in accelerating proteolytic cleavage of VWF by 
ADAMTS13 under mechanically induced fluid shear stress. In addition, a FVIII variant 
lacking the major VWF binding site (a3) in the light chain (i.e. FVIII-2RKR) has no 
effect in accelerating VWF proteolysis by ADAMTS13 under the same conditions20.  
The present study demonstrates for the first time that proteolytic cleavage of type 2N 
VWF variants by ADAMTS13 in the presence of FVIII is variably compromised. The 
impairment in FVIII-dependent proteolysis is proportional to the defects of their FVIII 
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binding. These results support the role of the VWF D’D3 domain and the VWF 
propeptide in regulating VWF proteolysis and suggest an evolutionary advantage by 
limiting VWF proteolysis in cases of VWD. 
 
3.3 Materials and Methods 
3.3.1 Constructs 
Plasmids encoding a human full-length wild-type (WT) VWF (pvW198.1) or various 
type 2N VWF variants including pvW198.8 (H817Q)22,23, pvW198.4 (R854Q)22,24,25, 
pvW198.7 (R782W)23, pvW198.9 (R782W/H817Q)23, and HPP-VWF23 were prepared as 
described previously.  These constructs were chosen because they represent a spectrum of 
FVIII binding affinity from nearly normal (i.e. H817Q) to severely defective (i.e. HPP-
VWF). The HPP (hereditary persistent propeptide)-VWF has two mutations: one from the 
gene (∆nt2269-2270) and the other by virtue of alternative splicing (∆nt2282-2288)26, 
resulting in the removal of furin cleavage site and persistence of the propeptide D1-D2 
domains. 
 
3.3.2 Preparation of plasma and recombinant VWF variants  
Plasma VWF was purified from normal human plasma according to the method described 
previously21. Serum-free conditioned media containing recombinant WT VWF and type 
2N VWF variants were prepared from transiently transfected HEK293T cells (kindly 
provided by Dr. David Ginsburg at University of Michigan, Ann Arbor, MI). The 
conditioned media were concentrated 50-100 times with a 150 kDa MWCO Pierce 
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concentrator (Thermo-Scientific, Rockford, IL) according to the manufacturer’s 
recommendation. The amount of purified plasma VWF was determined by absorbance at 
280 nm, corrected by absorbance at 320 nm (1 corrected absorbance at 280 nm equals to 
~1 mg/ml), while recombinant WT and 2N variants in the conditioned media were 
determined by ELISA using purified plasma VWF for a calibration standard27.  
 
3.3.3 Preparation of recombinant FVIII and ADAMTS13  
Recombinant full-length human ADAMTS13 and human FVIII were prepared as 
described previously20. The final purification products were buffer exchanged with 20 
mM HEPES, 0.15 M NaCl, and 5 mM CaCl2, pH 7.5, and stored at -80 °C until use. 
3.3.4 Quantitation of VWF concentrations by ELISA 
The concentrations of WT and type 2N VWF variants in the concentrated conditioned 
media were determined by an enzyme-linked immunosorbent assay (ELISA)27. Briefly, a 
high binding microtiter plate (Nagle NUNC International, Rochester, NY) was coated 
with 100 µl of rabbit polyclonal anti-VWF IgG (1:2,000) (Dako, Carpinteria, CA) 
overnight. The remaining binding sites were blocked for 30 min with 150 µl/well of 2.5% 
BSA in PBS. Conditioned media containing recombinant WT and type 2N VWF variants 
diluted with PBS were added and incubated for 2 hours. After being washed with PBS, 
monoclonal horseradish peroxidase (HRP)-conjugated rabbit anti-VWF IgG (1:5,000) 
(Dako) was added for detection. A chromogenic substrate, 3,3′, 5,5′-tetramethylbenzidine 
(TMB) (Invitrogen, Frederick, MD), was used to develop color and stopped with 1.5 M 
H2SO4. The absorbance at 450 nm was determined by a SpectraMax190 
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spectrophotometer (Molecular Devices, Sunnyvale, CA). Purified plasma VWF was used 
for a calibration standard. All assays were repeated at least three times for consistency.  
 
3.3.5 VWF multimer analysis  
VWF multimers of recombinant WT VWF and type 2N VWF variants in the conditioned 
medium were determined by fractionation by 1% or 2% agarose gel electrophoresis, 
followed by Western blotting as described previously20,28. 
 
3.3.6 Binding of FVIII or ADAMTS13 to type 2N VWF variants  
A high binding microtiter plate (Nagle Nunc International) was coated with 100 µl of 
rabbit polyclonal anti-VWF IgG (1:2,000) (Dako) overnight. The remaining binding sites 
were blocked for 30 min with 150 µl/well of 2.5% BSA in PBS. Recombinant WT and 
type 2N VWF variants diluted with PBS were added and incubated for 2 hours. After 
being washed with PBS, recombinant FVIII or ADAMTS13 at various concentrations 
was added and incubated for 1 hour. The bound FVIII or ADAMTS13 was detected by a 
monoclonal anti-FVIII HRP-conjugated antibody (1:3,000) (ESH-8HR) that recognizes 
the C2 domain in the light chain of FVIII (American Diagnostica Inc, Stamford, CT) or a 
monoclonal antibody against the disintegrin domain (1:5,000) (Green Mountain 
Antibodies, Burlington, VT), followed by a goat anti-mouse peroxidase-conjugated 
secondary antibody (1:5,000). A TMB (3,3′, 5,5′-tetramethylbenzidine) substrate  
(Invitrogen, Frederick, MD) was used for color reaction and stopped by addition of 1.5 M 
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H2SO4. The absorbance at 450 nm was determined on a SpectraMax190 microtiter plate 
reader (Mol. Devices). 
 
3.3.7 Binding of type 2N VWF variants to FVIII 
A high binding microtiter plate (Nagle Nunc International) was coated with 100 µl of 
sheep anti-FVIII IgG (1:2,000) (American Diagnostica Inc, Stamford, CT) overnight. The 
bound VWF was detected by rabbit anti-VWF (1:5,000) (A0082, Dako), followed by a 
goat anti-rabbit biotin-conjugated secondary antibody (1:5,000) and streptavidin-
conjugated peroxidase (1:1,000). A TMB (3,3′, 5,5′-tetramethylbenzidine) substrate  
(Invitrogen, Frederick, MD) was used for color reaction and stopped by addition of 1.5 M 
H2SO4. The absorbance at 450 nm was determined on a SpectraMax190 microtiter plate 
reader (Mol. Devices). 
 
3.3.8 Western blotting  
The proteolytic cleavage of VWF by ADAMTS13 under denaturing conditions or fluid 
shear stress was determined by Western blotting as described previously20,21,29. For assays 
under denaturing conditions, purified WT VWF and variants were pre-denatured at 37 °C 
for 2 hours with 1.5 M urea. The denatured VWF and variants (150 nM) were incubated 
with ADAMTS13 (0.2 nM) on a dialysis membrane floating on 5 mM Tris-HCl, pH 8.0, 
1.5 M urea at 37 °C for 4 hours. The digested materials were fractionated with 1% 
agarose gel electrophoresis. For assays under fluid shear stress, purified plasma VWF 
(pVWF) or recombinant WT and type 2N VWF variants in the conditioned medium (37.5 
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µg/ml, ∼150 nM subunits) were incubated with recombinant ADAMTS13 (5 nM) in the 
absence or in the presence of either a fixed concentration  (5 nM) or various 
concentrations of FVIII (0-20 nM) in 20 mM HEPES, pH 7.5 containing 1 mg/ml BSA, 
150 mM NaCl and 5 mM CaCl2 in a 0.2 ml thin-walled PCR tube with dome caps (total 
volume, 20 µl) for 30 min at 37 °C. The reaction mixtures were then subjected to mixing 
in a 96-well Eppendorf MixMate vortexer (Fisher-Thermo Scientific, Rockford, IL) at 
2,500 rpm for 2.5 min21,29. The reaction mixtures were then denatured at 100 ºC for 5 min 
with sample buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% sodium dodecyl 
sulfate, and 0.01% bromophenol blue). The denatured VWF was fractionated in a 5% 
Tris-glycine polyacrylamide gel in a Mini-protein III gel cassette (Bio-Rad, Hercules, 
CA) at 120V for 150 min. The proteins were then transferred onto a nitrocellulose 
membrane (Millipore, Billerica, MA) at 100 mA for 60 min. The proteolytic cleavage 
product of VWF (350 kDa, the dimer of C-terminal fragments) was detected by rabbit 
anti-VWF IgG (1:5,000) (Dako), followed by IRDye 800CW-labeled goat anti-rabbit IgG 
(1:20,000) (LI-COR Bioscience, Lincoln, NB) in TBS containing 1% casein and 0.05% 
Tween 20. The fluorescent signals were collected by an Odyssey infrared imaging system 
(LI-COR Bioscience)20. The cleavage products were quantified by NIH ImageJ software 
after the fluorescent intensities were converted into the gray image signals. 
 
3.3.9 ELISA for quantification of the cleaved VWF-A2 
Recombinant WT and 2N VWF variants in the conditioned media (150 nM) were 
incubated with various concentrations of recombinant FVIII (0-20 nM) for 30 min at 37 
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°C. Recombinant ADAMTS13 (5 nM) was added to the VWF-FVIII mixture and 
subjected to vortexing at 2,500 rpm for 2.5 min. The reaction was then terminated by 
addition of 50 mM EDTA. The reaction mixture was diluted 1:200-400 with 0.5% BSA 
in PBS and added to a high binding microtiter plate (Nagle NUNC), which was coated 
with 100 µl of monoclonal anti-VWF cleaved A2 IgG (MAB27642) (R&D Systems, 
Minneapolis, MN) (1 µg/ml) that specifically recognizes the N-terminus of cleaved VWF 
after amino acid residue Tyr1605, but not intact VWF30. Incubation was carried out for 2 
hours at 37 °C. After being washed with PBS, horseradish peroxidase (HRP)-conjugated 
rabbit anti-VWF IgG (1:5,000) (Dako) was added and incubated for 1 hour. A TMB 
substrate (Invitrogen, Frederick, MD) was used for color development. After being 
stopped with 1.5 M H2SO4, the absorbance at 450 nm was obtained from a 
SpectraMax190 spectrophotometer (Mol. Devices). Non-specific background absorbance 
resulted from binding of WT or a type 2N VWF variant to the wells without monoclonal 
anti-VWF A2 IgG was subtracted. Each sample was done three times for consistency. 
Statistical analysis was performed using one-way analysis of variance (ANOVA) or 
Student t-test. P values less than 0.05 was considered to be statistically significant. 
 
3.3.10 Ristocetin-induced platelet agglutination 
To assess the function of the expressed type 2N VWF variants to agglutinate platelets, 
lyophilized human platelets (Helena Laboratories, Beaumont, TX) were reconstituted 
with 20 mM Tris-HCl, pH 7.4, and 100 mM NaCl (20x106/µl). Lyophilized platelets (200 
µl) were incubated at 37°C with WT, type 2N VWF variants (15 µg/ml), or purified VWF 
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dimer (15 and 30 µg/ml) in the presence of 10 µl of normal human plasma (to provide 
fibrinogen) in a glass tube stirring at 1,100 rpm. The light transmission was recorded 
simultaneously in all channels for 6 minutes after addition of 1.0 mg/ml ristocetin with a 
PAP4 aggregation module (Bio/Data Corporation, Horsham, PA).  
 
3.3.11 Ristocetin and platelet-induced cleavage of 2N VWF variants by ADAMTS13 
under shear stress  
WT or type 2N VWF variants in conditioned medium (37.5 µg/ml) were incubated 
without or with lyophilized platelets (final concentration, 150 x 103/µl) and ristocetin (1.0 
mg/ml) in 20 mM HEPES, pH 7.5 containing 1 mg/ml BSA, 150 mM NaCl and 5 mM 
CaCl2 in a 0.2 ml thin-walled PCR tube with dome caps (total volume, 20 µl) for 30 min 
at 37 °C. Recombinant ADAMTS13 (5 nM) was added to the VWF/platelet/ristocetin 
mixture and subjected to vortexing at 2,500 rpm for 2.5 min as described previously21. 
The reaction mixtures were then denatured by heating at 100 ºC for 5 min with a sample 
buffer (62.5 mM Tris-HCl, pH 6.8 containing 25% glycerol, 2% sodium dodecyl sulfate, 
and 0.01% bromophenol blue). The proteolytic cleavage of VWF variants was 
determined by Western blotting as described in the previous section. 
 
3.4 Results 
3.4.1 Multimer distribution of the expressed recombinant type 2N VWF variants 
 
Previous studies have demonstrated that plasma VWF multimers in cases of type 2N 
VWD may be normal24,25,31, ultra large25,31,32, or reduced31,33, depending on the type of 
77 
 
mutations and zygosity. To determine the multimer distribution of recombinant type 2N 
variants expressed, serum-free media containing recombinant wild type VWF (WT) and 
type 2N variants (i.e. H817Q, R854Q, R782W, R782W/H817Q, and HPP-VWF) (Figure 
3.1A) were collected from transiently transfected HEK293T cells. VWF multimer 
analysis was performed using 1% (Figure 3.1B) or 2% (Figure 3.1C) agarose gel 
electrophoresis, followed by Western blotting as described in the Methods. As shown in 
Figure 3.1, on a low-resolution agarose gel (1%) the multimer distribution of WT and 
type 2N VWF variants was normal (Figure 3.1B). On a high-resolution agarose gel (2%), 
the HPP-VWF variant that contains an uncleaved propeptide was larger for each ladder as 
expected (Figure 3.1C). The multimers in other 2N variants--including H817Q, R854Q, 
R782W, R782W/H817Q--were also normal (Figure 3.1B and C). These results 
demonstrate that the type 2N VWF variants selected for the study do not demonstrate any 
defects in multimerization. 
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Figure 3.1. Schematic representation of  type 2N mutations, and multimer distribution of 
variants. Panel A. Human pro-VWF comprises a signal peptide, propeptide (D1-D2), furin 
cleavage site, D’-D3 domains, and A1-A2-A3 domains. In the distal C-terminus, there are D4-
C1-C2 and CK domains. The sites for FVIII binding, potential disulfide bond formation (-S-S-), 
and furin cleavage (blue arrow) are indicated. Mutations that result in type 2N VWD are indicated 
below the domain structure. They affect the furin cleavage site (i.e. HPP-VWF) or the D’-D3 
domain (i.e., H817Q, R854Q, and R782W). Panel B and Panel C show the VWF multimer 
distribution in the conditioned medium after being fractionated on 1% and 2% gel, respectively. 
Western blotting with rabbit anti-human VWF IgG (1:5,000) was used to visualize the VWF 
multimers. Purified plasma VWF (pVWF) was used as a normal control (Panels B and C, lane 7). 
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3.4.2 Binding of FVIII or ADAMTS13 to type 2N VWF variants  
Type 2N mutations primarily affect the D’-D3 domains of VWF that contain the FVIII 
binding sites9,11,16. Patients with the mutations exhibit variably reduced levels of plasma 
FVIII activity (0.02 to 0.40 IU/ml) and reduced FVIII binding10,16,17. To determine the 
total binding of FVIII to recombinant type 2N VWF variants, full-length FVIII at various 
concentrations (0-40 nM) was incubated with recombinant WT or type 2N variants 
captured by polyclonal anti-VWF IgG on a microtiter plate. The bound FVIII was 
detected by peroxidase-conjugated monoclonal anti-FVIII IgG as described in the 
Methods. As shown, FVIII bound type 2N VWF variants in a concentration-dependent 
manner, but with variably reduced affinities as compared with WT VWF. At any given 
concentration, the total amount of FVIII that bound to VWF was progressively reduced in 
the following order: WT>H817Q>R854Q> R782W>R782W/H817Q>HPP-VWF (Figure 
3.2A). When FVIII was immobilized on the microtiter plate and binding of WT and type 
2N VWF variants to FVIII was determined, the results were highly concordant (Figure 
3.2B).  
As three-body interactions between VWF, ADAMTS13, and FVIII are critical for 
proteolytic cleavage of VWF under fluid shear stress20, we determined the binding of 
ADAMTS13 to type 2N variants. The results showed that recombinant ADAMTS13 
bound WT and type 2N VWF variants with similar affinities under these conditions 
(Figure 3.2C). These results suggest that type 2N mutations do not affect the VWF-
ADAMTS13 interactions. 
80 
 
 
Figure 3.2. Binding of FVIII or ADAMTS13 to recombinant type 2N VWF variants. 100 µl 
of FVIII (0-40 nM) (Panel A) or ADAMTS13 (0-25 nM) (Panel C) was incubated with WT and 
type 2N variants captured by rabbit anti-VWF IgG (1 µg/well). Panel B shows the binding of 
VWF to immobilized FVIII captured by rabbit anti-FVIII IgG (1 µg/well). Bound FVIII, VWF or 
ADAMTS13 was determined by peroxidase-conjugated monoclonal anti-FVIII IgG (1:2,000) 
(Panel A), anti-VWF IgG (1:5,000) (Panel B) or anti-V5 IgG (1:1,000) (Panel B), followed by 
incubation with TMB substrate. The specific binding was determined by the total absorbance at 
450 nm in the presence of VWF minus that in the absence of immobilized VWF. The results are 
the mean from three independent experiments (n=3). 
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3.4.3 Cleavage of type 2N variants by ADAMTS13 under denaturing conditions is normal 
To determine whether mutations on the D’D3 domain or at the cleavage site of VWF affect 
overall susceptibility to proteolysis, WT and type 2N or HPP-VWF variants were pre-denatured 
with 1.5% urea and then incubated with recombinant ADAMTS13 (0.4 nM) for 4 hours. The 
cleavage of pre-denatured VWF was determined by 1% agarose gel and Western blotting as 
described in the Methods. The cleavage of type 2N (H817Q, R854Q, R782W, and compound 
heterozygous R782W/H817Q) or HPP-VWF variants to ADAMTS13 proteolysis under static and 
denaturing conditions was quite similar to the cleavage of WT VWF (Figure 3.3A). No 
statistically significant difference in the cleavage product formation was observed among all the 
VWF variants and between the variants and WT VWF (p>0.05) (Figure 3.3B). These results 
suggest that there is no intrinsic defect in the susceptibility of type 2N or HPP-VWF to 
proteolysis by ADAMTS13 under static and denaturing conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
Figure 3.3. Western blotting analysis of the proteolytic cleavage of type 2N VWF variants in 
the presence of FVIII under denaturing conditions. WT and type 2N VWF variants (150 nM) 
pre-denatured with 1.5 M urea were incubated with ADATMS13 (0.4 nM) in the absence (-) or in 
the presence (+) of EDTA (20 mM) at 37 °C for 4 hours on a dialysis membrane floating over 5 
mM Tris-HCl, pH 8 and 1.5 M urea. The proteolytic cleavage of VWF was determined by 1% 
agarose gel electrophoresis and Western blot (Panel A). Relative cleavage efficiency was 
quantified from the ratio of the cleavage product (arrowhead) to the high molecular weight VWF 
(HMW), which was normalized to 1 for WT. One-way ANOVA analysis of variance was used to 
determine the significance of differences among the group with a p value of greater than 0.05.  
The means and standard errors of the means from three independent experiments are shown 
(Panel B). 
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3.4.4 Compromised proteolytic cleavage of type 2N VWF variants by ADAMTS13 in the 
presence of FVIII under fluid shear stress 
Our previous studies have shown that binding of FVIII alone20 or in combination with 
platelets21 to VWF dramatically enhances proteolytic cleavage of VWF by ADAMTS13 
under fluid shear stress. We tested the hypothesis that type 2N mutations that result in 
reduced FVIII binding may affect FVIII-dependent proteolysis of VWF under shear 
stress. As shown, in the absence of FVIII, the VWF cleavage product of 350 kDa was 
barely detectable. In the presence of 5 nM FVIII, the cleavage product increased 
dramatically for WT VWF (∼ 9 fold).  
However, the fold increase in the cleavage product for the type 2N VWF variants was 
reduced in the following order: H817Q>R854Q> R782W>R782W/H817Q>HPP-VWF 
(Figure 3.4). There was nearly normal cleavage for H817Q and severely defective 
cleavage for HPP-VWF under these conditions.  
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Figure 3.4. Western blotting analysis of the proteolytic cleavage of type 2N VWF variants in 
the presence of FVIII under fluid shear stress. WT and type 2N VWF variants in conditioned 
medium (∼150 nM) were incubated with ADAMTS13 (∼5 nM) in the absence (-) or in the 
presence (+) of a fixed concentration of FVIII (5 nM) at 25 ºC for 2.5 min under vortexing-
induced fluid shear stress (rotation rate, 2,500 rpm). EDTA (20 mM) (+) was included in lane 3 
as a negative control. Western blotting with rabbit anti-VWF IgG (1:5,000) was used to determine 
the cleavage product (∼350 kDa) indicated by the arrowhead (Panel A). Quantitation of the 350 
kDa bands was performed using ImageJ software (Panel B). The results (mean ± standard error, 
n=3) were expressed as the fold increase in the cleavage product from WT and type 2N variants 
in the presence of FVIII relative to that in the absence of FVIII. 
 
Additional evidence from the kinetic study further supports this hypothesis. In the 
presence of increasing concentrations of FVIII (0-20 nM), the proteolytic cleavage of 
type 2N VWF variants remained variably reduced as compared with that of WT VWF, 
assessed either by our novel quantitative ELISA (Figure 3.5) or Western blotting (Figure 
3.6). There was severely impaired proteolytic cleavage of R782W/H817Q and HPP-VWF 
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by ADAMTS13 even in the presence of 20 nM FVIII (Figure 3.4 and Figure 3.5). 
Together, these results demonstrate that naturally occurring type 2N VWF variants that 
are defective in FVIII binding are also compromised in proteolytic cleavage by 
ADAMTS13 in the presence of FVIII under physiologically relevant fluid shear stresses.   
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Figure 3.5. Kinetic analysis of proteolytic cleavage of type 2N VWF variants in the presence 
of various concentrations of FVIII under fluid shear stress. WT or type 2N VWF variants 
(150 nM) were incubated with ADATMS13 (5 nM) at 25 °C for 2.5 min in the presence of 
various concentrations of FVIII (0-20 nM) under vortex induced fluid shear stress (rotation rate, 
2,500 rpm). The proteolytic cleavage of VWF at the specific Tyr-Met bond was determined by an 
ELISA described in detail in the Methods. The percentage of cleaved VWF as a function of 
increasing concentrations of FVIII observed in WT and type 2N VWF variants (Panel A) or the 
relative fold reduction of the cleavage product formation in type 2N VWF variants compared with 
that in WT (Panel B) in the presence of 20 nM of FVIII was presented (mean ± standard error) 
from three independent experiments (n=3). One (*) and two stars (**) indicated that the 
difference in the cleavage product formation between a type 2N variant and WT VWF was 
statistically significant (p<0.05) and highly significant (p<001), respectively. 
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Figure 3.6. Western blotting analysis of the proteolytic cleavage of type 2N VWF variants in 
the presence of various concentrations of FVIII under fluid shear stress. Panel A. Purified 
plasma VWF (pVWF) (as a reference), WT or type 2N VWF variants in the conditioned medium 
(∼150 nM) were incubated at 25°C for 2.5 min under fluid shear stress with ADAMTS13 (∼5 
nM) in the presence of and various concentrations of FVIII (0-20 nM). EDTA (20 mM) was 
included in lane 1 for a negative control in each blot. The cleavage product (∼350 kDa) was 
determined by SDS-polyacrylamide gel (5% Tris-glycine) electrophoresis and Western blotting as 
described in the Methods. Panel B. The quantitation of the specific cleavage product (~350 kDa) 
was performed using ImageJ software. The fold increase (mean ± standard error) was expressed 
as a function of FVIII concentrations from three independent experiments (n=3). 
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3.4.5 Type 2N VWF variants are normal or nearly normal in ristocetin-induced platelet 
aggregation 
Ristocetin, an antibiotic that specifically binds the A1 domain of VWF, modifies 
interaction between VWF-A1 and the platelet receptor glycoprotein 1bα (GP1bα)4. Type 
2N mutations located in the D’D3 domain of VWF are not expected to affect VWF-
platelet interaction. To assess the function of type 2N VWF variants, commercially 
available and lyophilized platelets from healthy donors were incubated with type 2N 
VWF variants in the presence of 1.0 mg/ml ristocetin and a small amount (5%) of normal 
human plasma (to provide fibrinogen). The percentage of platelet aggregation was 
determined by a light transmission approach. The results showed that the total final 
aggregation of lyophilized platelets in the presence of the same final concentration (15 
µg/ml) of WT, H817Q, R854Q, R782W, R782W/H817Q, and HPP-VWF was 86%, 65%, 
73%, 65%, 73%, and 50%, respectively (Figure 3.7A).  
To rule out the possibility that adding a small amount of normal human plasma into the 
reaction may obscure the results in assessing platelet aggregation, a dimeric VWF (500 
kDa) (Figure 3.7B, inset) (15 or 30 µg/ml), isolated by size exclusion chromatography, 
was used in the same assay. No agglutination or aggregation of lyophilized platelets was 
observed, while plasma-derived multimeric VWF aggregated platelets normally (Figure 
3.7B), suggesting that a small amount of normal human plasma added into the assay is 
not sufficient to cause normal platelet aggregation without the supplement of functional 
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multimeric VWF. Together, these results demonstrate that the type 2N VWF variants are 
normal or nearly normal for agglutinating platelets enhanced by ristocetin. 
 
Figure 3.7. Effect of type 2N mutations on ristocetin-induced platelet agglutination and 
VWF proteolysis by ADAMTS13. WT and type 2N VWF variants (15 µg/ml) were incubated 
with lyophilized human platelets (20x106/µl) in the presence of 5% normal human plasma and 1.0 
mg/ml ristocetin (Panel A). The light transmission was recorded simultaneously in all channels 
for 6 minutes at 37°C. Multimeric VWF (WT) (15 µg/ml) or dimeric VWF (Dimer) (15 and 30 
µg/ml) purified from plasma (Inset) was incubated with lyophilized human platelets (20x106/µl), 
5% normal human plasma, and 1.0 mg/ml ristocetin (Panel B). The light transmission was 
recorded simultaneously in all three channels for 6 minutes at 37°C. An increase in light 
transmission is indicative of platelet agglutination and aggregation. The inset shows the multimer 
distribution of WT and dimeric VWF by 1% agarose gel electrophoresis and Western blotting.  
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3.4.6 Proteolytic cleavage of type 2N VWF/platelet complexes by ADAMTS13 in the 
presence of ristocetin  
Binding of platelets in the presence of ristocetin appears to alter VWF conformation by a 
different mechanism from FVIII, thereby accelerating proteolytic cleavage of VWF by 
ADAMTS1321. To assess the effect of ristocetin/platelets on proteolysis of type 2N 
variants, WT or variants were incubated with ADAMTS13 in the presence of lyophilized 
platelets and ristocetin for 5 min under constant shear stress. Proteolytic cleavage was 
determined by 5% SDS-polyacrylamide gel electrophoresis and Western blotting as 
described previously21. We showed that the cleavage of all type 2N variants, except for 
HPP-VWF, was quite similar to that of WT-VWF (Figure 3.8). However, there was a 
statistically significant reduction (42%) in the cleavage product of HPP-VWF, compared 
with WT (p<0.01) (Figure 3.8B). These results suggest that HPP-VWF binds platelets 
nearly normally under static conditions, but appears to be moderately compromised in 
ristocetin/platelet enhanced proteolysis under fluid shear stresses. 
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Figure 3.8. Effect of type 2N mutations on ristocetin-induced VWF proteolysis by 
ADAMTS13. Panel A. WT or type 2N VWF variants in the conditioned medium (∼150 nM) 
were incubated with lyophilized platelets (150x103/µl) in the presence of ristocetin (1.0 mg/ml) at 
25 °C for 2.5 min under fluid shear stress. The proteolytic cleavage of VWF was determined by 
5% SDS-polyacrylamide gel and Western blotting as described in the Methods. Panel B. ImageJ 
densitometry was used to determine the relative fold increase in the presence of ristocetin and 
platelets and compared with that in the absence of both. The data presented (mean ± standard 
error) is from three independent experiments (n=3). Statistical analysis was performed using 
Student’s t-test. Double stars indicate that the difference in the VWF cleavage product formation 
between WT and HPP-VWF was statistically significant (p<0.01). 
 
3.5 Chapter Discussion 
The present study demonstrates for the first time that naturally occurring VWF mutations 
(i.e. H817Q, R854Q, R782W, R782/H817Q, and HPP-VWF) found in cases of type 2N 
VWD result in compromised proteolysis by ADAMTS13 in the presence of FVIII under 
fluid shear stress (Figures 3.4, 3.5, and 3.6), but not under denaturing conditions (Figure 
A 
B 
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3.3). The reduced proteolytic cleavage of the 2N variants appears to be proportional to 
the impairment of their FVIII binding (Figure 3.2). For instance, H817Q, which results in 
mild defects for FVIII binding, exhibits nearly normal cleavage by ADAMTS13 in the 
presence of various concentrations of FVIII, while HPP-VWF, which results in the most 
severe defects for FVIII binding, is dramatically impaired in proteolysis by ADAMTS13 
under the same conditions (Figures 3.4, 3.5, and 3.6). Even in the presence of high 
concentrations of FVIII (20 nM), no enhancement of the cleavage product formation, 
assessed either by ELISA (Figure 3.5) or by Western blotting (Figures 3.4 and 3.6), was 
detected.  These results are reminiscent of those we have reported previously, in which a 
FVIII variant with a major VWF binding site (a3) removed (i.e. FVIII-2RKR) did not 
enhance the proteolytic cleavage of WT VWF by ADAMTS13 under fluid shear 
stress20,21. Together, these findings, both from the investigation of the mutant cofactor 
(i.e. FVIII) and the mutant substrate (i.e. VWF), underscore the critical role of FVIII-
VWF interactions in regulating proteolysis of VWF under physiologically relevant 
conditions.  
To date, quantitation of the specific cleavage of multimeric VWF at the Tyr1605-Met1606 
bond by ADAMTS13 has been cumbersome and problematic. The detection of the 350 
kDa product (the dimer of two C-terminal fragments) requires simultaneous cleavage of 
two adjacent Tyr-Met bonds, which occurs rarely under physiological conditions. Our 
novel ELISA-based assay detects the N-terminal peptide (i.e. EQAPNVY) resulting from 
cleavage after the Tyr residue occurring anywhere along a VWF multimer, which 
dramatically increases the assay sensitivity. Furthermore, the assay is highly specific for 
detecting the ADAMTS13 cleavage product, but not from the cleavage by other 
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leukocyte proteases such as cathepsin G, proteinase 3, and elastase (Figures 3.9 and 
3.10), which are known to cleave VWF at or near the Tyr1605-Met1606 bond33. This 
sensitive and reproducible ELISA assay will fundamentally change how we assess the 
biological activity of ADAMTS13.  
 
Figure 3.9. Validation of the novel ELISA method for assessing proteolytic cleavage of VWF 
by ADAMTS13. Panel A. Schematic representation of the A1-A2-A3 domains of a mature VWF 
subunit, the cleavage site for ADAMTS13, cathepsin G, elastase, and proteinase 3, as well as the 
binding site for the monoclonal anti-VWF A2 IgG. Panels B to E show the signals (absorbance at 
450 nm) detected by ELISA after 10 min of incubation of pre-denatured WT VWF (150 nM) with 
ADAMTS13 (0-40 nM) (Panel B), cathepsin G (0-36 nM) (Panel C), proteinase 3 (0-400 nM) 
(Panel D), and elastase (0-400 nM) (Panel E).  
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It remains somewhat puzzling why the ELISA does not detect the cleavage of VWF by 
cathepsin G, which also cleaves the Tyr-Met bond. This may be related to the additional 
cleavages occurring elsewhere on VWF as demonstrated previously33, which may destroy 
the binding epitopes for anti-cleaved A2 IgG (capturing antibody) or anti-VWF IgG 
(detecting antibody). Moreover, the N-terminal cleavage products resulting from 
digestion with proteinase 3 (Figure 3.9D and 3.10C) and elastase (Figure 3.9E and 
3.10A) contains two extra amino acids (methionine and valine), which may block the 
binding of the anti-cleaved A2 antibody. In addition, similar non-specific cleavage of 
VWF elsewhere by proteinase 3 and elastase was reported33, resulting in the loss of 
antibody binding epitopes necessary for detection. A linear increase (by ELISA) as 
opposed to a plateau (by Western blotting) of the cleavage product of WT VWF as a 
function of increasing concentrations of FVIII (Figure 3.6) supports the assertion that our 
novel ELISA is a much better assay for assessing ADAMTS13 activity.  
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Figure 3.10. Proteolytic cleavage of VWF by leukocyte proteases. VWF (∼150 nM) was 
incubated with elastase (200 nM, Panel A), cathepsin G (20 nM, Panel B), or proteinase 3 (200 
nM, Panel C) at 25 °C for 2.5 min under fluid shear stress. The proteolytic cleavage of VWF was 
determined by 5% SDS-polyacrylamide gel and Western blotting as described in the Methods. 
 
These results, although interesting, present a significant question about the physiological 
relevance of having compromised proteolysis of VWF in cases of type 2N VWD. The 
clinical phenotype in patients with type 2N VWD is usually mild, with bleeding episodes 
only after trauma or surgery. It has been postulated that plasma FVIII clotting activity is 
the major determinant of the clinical phenotype. We hypothesize that plasma VWF may 
play a role in modulating bleeding severity. For instance, patients with HPP-VWF or 
R763G, which disrupts the furin cleavage site and results in a persistence of the 
propeptide, exhibit dramatically reduced plasma FVIII activity (as low as 0.05-0.1 
U/ml)23,25. However, plasma VWF multimers in these patients are smeary or ultra large in 
A 
B 
C 
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size with no visible satellite bands25. This evidence is consistent with the notion of 
impaired proteolysis of VWF by ADAMTS13 in vivo. In addition, the cleavage of HPP-
VWF by ADAMTS13 in the presence of ristocetin and platelets is also modestly reduced 
(Figure 3.8), despite its nearly normal activity in agglutinating lyophilized platelets 
induced by ristocetin (Figure 3.7). The discrepancy between the nearly normal platelet 
agglutination and reduced ristocetin/platelet-accelerated cleavage may lie in the assay 
conditions.  The cleavage assay is done under fluid shear stress (∼32 dynes/cm2), while 
the platelet agglutination assay is performed in the (relative) absence of shear. The 
reduced proteolysis of VWF in cases of type 2N VWD may have a protective role in 
mitigating bleeding tendency.  
In summary, we demonstrate that recombinant type 2N VWF variants exhibit normal or 
expected patterns of multimerization, normal binding to ADAMTS13, and normal to 
subnormal platelet agglutination in the presence of ristocetin, but variably reduced FVIII 
binding. More importantly, the proteolytic cleavage of type 2N VWF variants by 
ADAMTS13 is variably reduced in the presence of FVIII under fluid shear stress. The 
impairment of ADAMTS13-mediated proteolysis of these variants appears to be 
correlated primarily with the defects in their FVIII binding or partially with platelet 
binding under fluid shear stress as in the case of HPP-VWF. Our findings, by examining 
the susceptibility of naturally occurring type 2N VWF mutants to ADAMTS13, further 
underscore the important role of FVIII and propeptide in regulating VWF proteolysis 
under physiologically relevant shear stresses. We speculate that this may have an 
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evolutionary advantage by limiting proteolytic cleavage of a hemostatic protein like 
VWF in the case of a bleeding disorder such as VWD. 
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4.1 Overview 
Previous studies have shown that ADAMTS13 spacer domain is required for recognition 
and cleavage of von Willebrand factor (VWF) under static/denaturing conditions. 
Sequence alignment of the spacer domains from human, murine and zebrafish 
ADAMTS13 with those from human and murine ADAMTS1, a closely related member 
of the ADAMTS family, has allowed us to identify a potential motif Arg
659
-Arg-Tyr-Gly-
Glu-Glu
664
 (or RRYGEE) within the spacer domain of human ADAMTS13 that may 
participate in substrate recognition. A deletion of all these six amino acid residues 
(RRYGEE) from the ADAMTS13 spacer domain (construct del6aa) resulted in 
dramatically reduced proteolytic activity toward VWF73 peptide, denatured VWF, native 
VWF under fluid shear stress, and ultra large VWF on endothelial cells. Site-directed 
mutagenesis, kinetic analyses, and peptide inhibition assays have further identified the 
important role of the amino acid residues Arg
659
, Arg
660
 and Tyr
661
 (or RRY) in 
proteolytic cleavage of various substrates under both non-physiological and physiological 
conditions. In addition, modification of an exosite in the spacer domain generated 
ADAMTS13 variants with reduced inhibition by anti-ADAMTS13 IgGs while preserving 
or enhancing specific activity. Molecular modeling using the existing crystal structure of 
ADAMTS13-DTCS fragment and VWF-A2 domain indicated a shift in hydrophobicity 
and subsequent opening of the VWF-A2 binding pocket on the ADAMTS13 spacer 
domain, potentially resulting in increased hydrophobic interactions in the pocket and 
hydrogen bonding on the exterior of the pocket. Together, these results shed light on the 
importance of exosite binding in the spacer domain in the substrate recognition and 
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pathogenesis of acquired TTP. Furthermore, the crystallization, screening, data 
collection, and structure determination for an autolysis product of ADAMTS13, the 
ADAMTS13-CS fragment, provides the basis for beginning crystallization studies of 
complexes to probe amino acid specificity of ADAMTS13 exosite binding with VWF 
and autoantibody recognition.  
 
4.2 Introduction 
ADAMTS13-Spa appears to directly interact with the distal portion (amino acid residues 
Glu1660-Arg1668) of the VWF73 peptide11. The deletion of these C-terminal 9 amino acid 
residues from the VWF73 results in dramatically reduced proteolytic cleavage of the 
shorter peptide by ADAMTS13 under static conditions. The importance of ADATMS13-
Spa is also highlighted by the fact that this region is frequently targeted by anti-
ADAMTS13 autoantibodies in patients with acquired TTP12,13,14. Epitope mapping 
studies have suggested that the anti-ADAMTS13 immunoglobulin G (IgG) in some TTP 
patients specifically binds the amino acid residues between Tyr572 and Asn579 or between 
Val657 and Gly666 on the ADAMTS13 spacer domain14,15,16,17,18.  
Both antibody mapping results and sequence alignment findings provide hints to 
investigate the role of the amino acid residues between Arg659 and Glu664 in the 
ADAMTS13 spacer domain in substrate recognition. Our lab has published data that 
demonstrate the critical role of the amino acid residues Arg
659
, Arg
660
 and Tyr
661
 (RRY) 
within the ADAMTS13 spacer domain in proteolytic cleavage of various substrates 
including VWF73, denatured VWF, native VWF under fluid shear stress, and cell bound 
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UL-VWF under static and fluid shear stress conditions11. In this chapter, I will present 
my work done in this project, which included some work on peptide inhibition assays and 
molecular modeling of the spacer domain with our designed peptide. 
In another recent study19, our lab hypothesized that a modification of the exosite site 3 in 
the spacer domain of ADAMTS13 might generate ADAMTS13 variants with reduced 
inhibition by anti-ADAMTS13 IgGs in patients with acquired TTP, while their 
proteolytic activity was preserved or enhanced19. To test this hypothesis, we engineered a 
series of novel recombinant ADAMTS13 variants by replacing several surface charged or 
hydrophobic residues in the exosite 3 of the spacer domain of ADAMTS13 with those 
that have similar chemical structure. Proteolytic activity and sensitivity of these novel 
ADAMTS13 variants to inhibition by patients’ autoantibodies were assessed. We showed 
that two of twenty-four novel ADAMTS13 variants exhibit enhanced specific proteolytic 
activity, but are more resistant to inhibition by anti-ADAMTS13 autoantibodies in at 
least 10/12 patients with acquired TTP19. These novel gain-of-function and autoantibody-
resistant variants may be applicable for therapeutics of acquired TTP patients with 
inhibitors, as well as hereditary TTP. In this chapter, I will present my work done in this 
project, which included molecular modeling of the WT and mutants spacer domains with 
the VWF-A2 domain. 
Finally, in the search to determine the ADAMTS13 exosite binding with VWF and 
autoantibody recognition sites on ADAMTS13, we sought to crystallize the full-length 
ADAMTS13 protein. The structures of the ADAMTS13-DTCS fragment, obtained at 
2.6-Å and 2.8-Å resolution, revealed linearly distributed exosites that recognize distinct 
substrate regions22. With intimate knowledge of the full-length structure of ADAMTS13, 
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which includes the Metalloprotease and C-terminal domains, we can begin to probe 
amino acid specificity of ADAMTS13 exosite binding with VWF and autoantibody 
recognition. This chapter describes the crystallization, screening, data collection, and 
structure determination for an autolysis product of ADAMTS13, the ADAMTS13-CS 
fragment. 
 
4.3 Materials and Methods 
4.3.1 Preparation of recombinant ADAMTS13 
For stable expression, Chinese hamster ovary (CHO-s) cells were used. Cells were 
cultured in 6-well plate and transfected with plasmid DNA mixed with lipofactmine-2000 
(Invitrogen) (1:3 weight to volume) in serum-free medium. The cells were selected under 
G418 (1 mg/ml) for 10-15 days. The clones expressing ADAMTS13 were identified by 
Western blotting or immunofluorescent staining. The expression of ADAMTS13 was 
carried out in 3-layer tissue culture flasks with serum-free DMEM/F12 medium without 
phenol supplemented with insulin, transferrin, and selenium (Roche). Conditioned 
medium was collected every day for 10 days. The recombinant ADAMTS13 (His-V5 
tagged) was purified with ion exchange and Ni-chelating affinity chromatographies as 
previously described23. The amount of the purified proteins was determined by 
absorbance at 280 nm (corrected with light scattering at 320 nm) (1 corrected absorbance 
at 280 nm equals to ~0.68 mg/ml for full-length and mutant ADAMTS13) as described 
previously
24
. 
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The FL-ADAMTS13 for crystallization screening was a kind gift from Baxter 
Pharmaceuticals (F. Scheiflinger). 
 
4.3.2 Preparation of recombinant fluorescein-labeled VWF73 
A plasmid encoding VWF73 with substitutions by 2 cysteine residues at the amino 
residues Gln1599 and Pro1611 flanking the Tyr-Met bond was a kind gift from Dr. John 
Owen (Department of Medicine, Wake Forest University School of Medicine). 
Recombinant VWF73 was expressed, purified, and labeled with fluorescein-5-maleimide 
(Pierce). The amount of purified fluorescein-labeled VWF73 designated rF-VWF73 was 
determined by the absorbance at 280 nm (1 corrected absorbance at 280 nm equals to 
~0.94 mg/ml). Because of the homo-quenching effect resulting from close proximity of 2 
labeled-fluorescent dyes, no fluorescence emits. When the Tyr-Met bond is cleaved by 
ADAMTS13, 2 fluorescent dyes are separated, and fluorescence emits at excitation 
wavelength of 485 nm, which can be detected at the emission wavelength of 
approximately 540 nm. 
 
4.3.3 Preparation of synthetic peptides 
Several short amino acid peptides corresponding to the amino acid residues (Arg659-
Glu664 or RRYGEE) of ADAMTS13 spacer domain were chemically synthesized at 
Peptide 2.0 (Chantilly, VA). Three perfectly matched peptides (RRYGEE, RRY and 
GEE) and 2 scrambled peptides with identical amino acid residues (EGRYR and RYR) 
were synthesized. All peptides were purified by HPLC to greater than 92% in purity. The 
Mass spectrometry analysis showed that the masses [M +2H+]2+ for RRYGEE, EGRYR, 
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RRY, RYR, and GEE were 406.2, 406.2, 248.5, 248.5, and 335.0, respectively. The 
peptides were lyophilized and supplied in 0.1% trifluoroacetate salt. For reconstitution, 
distilled water was added to concentration of 10 mg/ml. The stock peptides were stored in 
aliquots at -80 ºC. 
 
4.3.4 Proteolytic cleavage of fluorescein-labeled VWF73 peptide 
Maleimide-fluorescein-labeled VWF73 derived from the central A2 domain of VWF (i.e. 
rF-VWF73) (2 µM) was incubated with ADAMTS13 (0.2 nM) in 5mM Bis-Tris, pH 6.0 
containing 25 mM CaCl2 and 0.005% Tween 20 in a total volume of 200 µl in a 96-well 
white plate (Corning, NY). The rate of fluorescence generation was monitored at 37 ºC 
with a fluorescent microtiter plate reader (Molecular Devices, Sunnyvale, CA) (Ex/Em 
485/535nm) every minute for 30 min. Pooled NHP was used as a reference. Each sample 
was assayed three times. The data were expressed as means and standard errors of the 
means (Mean ± SEM). The relative proteolytic activity compared with that in wild type 
ADAMTS13 was plotted against ADAMTS13 variants.  
For the peptide inhibition assay, rF-VWF73 (1 µM) was incubated with various 
concentrations (0-200 µM) of synthetic peptides as indicated for 10 min. Then 
recombinant ADATMS13 (2 nM) was added and proteolytic cleavage of rF-VWF73 was 
monitored at 37 ºC on a fluorescent microtiter plate reader (Gemini XPS) (Ext. 485 nm 
and Emission 540 nm) every minute for 20 min. The maximal rate of fluorescent 
generation per second (units/sec) was determined by SoftMax Pro® software version 7.0 
and plotted against the log concentrations of synthetic peptides used. The experiments 
were repeated under the same conditions for three times. The concentration achieving 
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half maximal inhibition (IC50) was determined by fitting the data into a non-linear 
equation using GraphPad Prism software (La Jolla, CA).  
 
4.3.5 Proteolytic cleavage of multimeric VWF 
Purified plasma VWF (150 nM) was incubated with wild type ADAMTS13 and variants 
in the conditioned medium at the final concentrations of 0.2 nM and 0.04 nM or 2 nM 
and 10 nM in the purified forms (total volume 150 µl) at 37 °C for 4 hours on a dialysis 
membrane (0.25 µm, pore size) floating over 50 ml dialysis buffer (10 mM Tris-HCl, pH 
8.0 containing 1.5 M urea in a conical tube. The digested material (50 µl) was withdrawn 
and denatured with 50 µl sample buffer (70 mM Tris-HCl, pH6.5, 2.4% SDS, 0.67 M 
urea, and 4 mM EDTA) at 60 °C for 20 minutes. The denatured VWF was fractionated 
with 1% (wt/vol) SeaKem HGT agarose (Cambrex, East Rutherford, NJ) gel in a Mini-
protein III gel cassette (Bio-Rad, Hercules, CA), 15 mA for 90 min. The protein was then 
transferred onto a nitrocellulose membrane (Millipore, Billerica, MA), 100 mA for 20 
min. The proteolytic cleavage of VWF multimers were detected by Western blotting with 
rabbit anti-VWF IgG (1:5,000) and IRDye 800CW-labeled goat anti-rabbit IgG 
(1:10,000) (LI-COR Bioscience, Lincoln, Nebraska) in TBST containing 1% casein. The 
fluorescent signal was determined by an Odyssey infrared imaging system (LI-COR 
Bioscience, Lincoln, Nebraska). The relative proteolytic activity was determined by 
densitometry of the cleavage product and uncleaved high molecular weight VWF 
multimers.   
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4.3.6 Crystallization screening and optimization 
Initial screening for crystallization conditions for FL-ADAMTS13 was carried out by the 
hanging-drop vapor-diffusion method using Index Screen, Crystal Screen, SaltRx Screen, 
PEG/Ion Screen, Grid Screen MPD and Grid Screen Ammonium Sulfate kits (Hampton 
Research, Aliso Viejo, California, USA). A volume of 1 µl protein solution was manually 
mixed with an equal amount of reservoir solution and the droplets were allowed to 
equilibrate against 0.5 ml reservoir solution at 4°C and 25°C. 
 
4.3.7 Data collection and structure refinement 
X-ray data were collected to their diffraction limit and were processed using DENZO.33 
The structure was determined by molecular replacement using AmoRe.34 The initial 
phases were improved by non-crystallographic symmetry (NCS) averaging and solvent 
flattening using DPHASE (S. Stayrook, personal communication). The resulting electron 
density maps were fit using Coot.35 The structure was refined using CNS.36 Refinement 
included simulated annealing, restrained isotropic temperature factor refinement, a bulk 
solvent correction, and monitoring of the free R-factor with 5% of the data omitted. NCS 
restraints were imposed. Figures were prepared using MOLSCRIPT,37 Coot,35 and 
PyMol. 
4.3.8 Molecular modeling 
The interaction between the spacer domain of ADAMTS13 and RRYGEE or VWF73 
peptide was modeled using the HHPred server plugin using an energy minimization 
algorithm (GROMACS4) in PyMol software (http://www.pymol.org/).  
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4.4 Results 
4.4.1 Synthetic peptides derived from the ADAMTS13 spacer domain or an isolated 
spacer domain of ADAMTS13 inhibits proteolytic cleavage of VWF by ADAMTS13 
Deletion of several amino acid residues or substitution of a single amino acid residue 
within the spacer domain may result in protein structural change or misfolding. To rule 
out such a possibility, we synthesized short peptides based on amino acid sequence of the 
RRYGEE motif in ADAMTS13 spacer domain and used these synthetic peptides for the 
inhibition assays. The peptides RRYGEE and RRY, which perfectly match the sequence 
of spacer domain, dramatically inhibited proteolytic cleavage of rF-VWF73 (Figure 
4.1A) and multimeric VWF (Figure 4.1B-E) by wild-type ADAMTS13 in a 
concentration-dependent manner. At 200 µM, RRYGEE and RRY inhibited proteolytic 
cleavage of rF-VWF73 by ADAMTS13 activity by approximately 85% and 90%, 
respectively.  
The synthetic peptide GEE, and scrambled peptides RYR and EYREGR, however, 
exhibited much less inhibitory activity on proteolytic cleavage of rF-VWF73 even at the 
highest concentration (200 µM) tested (Figure 4.1A). The inhibitory effect of RRYGEE 
(Figure 4.1B) and RRY (Figure 4.1C) was also observed in proteolytic cleavage of 
multimeric VWF under fluid shear stress.  
The IC50s were estimated to be less than 50 µM for both peptides (Figure 4.1F). The 
peptides GEE (Figure 4.1D) and RYR (scrambled) (Figure 4.1E) at concentration of 200 
µM did not exhibit significant inhibitory effects in this assay. Together, these data 
suggest that the amino acid residues Arg659, Arg660 and Tyr661 in the ADAMTS13 spacer 
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domain may involve in direct binding interaction with the central A2 domain of soluble 
VWF that is exposed by truncation or under high fluid shear stresses. 
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Figure 4.1. Synthetic peptides derived from ADAMTS13 spacer domain inhibit cleavage of 
VWF73 and multimeric VWF by ADAMTS13. Panel A. rF-VVWF73 peptide (1 µM) was 
incubated with various concentrations (0-200 µM) of synthetic peptides as indicated for 10 min. 
Then recombinant ADATMS13 (2 nM) was added and proteolytic cleavage of rF-VWF73 was 
monitored at 37 ºC on a fluorescent microtiter plate reader every minute for 20 min. The maximal 
rates of fluorescent generation per second were plotted against the log concentrations of synthetic 
peptides used. The data presented are means ± SD of three independent measurements. Panel B to 
E. Purified plasma-derived VWF (37.5 µg/ml) was incubated at 37 ºC with various 
concentrations (0-200 µM) of synthetic peptides RRYGEE (Panel B) or RRY (Panel C) or GEE 
(Panel D) or RYR (Panel E) in the absence or presence of 20 mM EDTA for 60 min. Then, 
ADAMTS13 (50 nM), recombinant FVIII (10 nM), and lyophilized platelets (210x10
6
/ml) were 
added into the reaction. The reaction mixture was subjected to vortexing (2,500 rpm) for 5 min. 
The proteolysis of VWF was determined by multimer analysis on 1% agarose gel and Western 
blot. High molecular weight multimer is indicated as HMW. The proteolytic cleavage product 
(350 kDa) is indicated with the arrowhead. Panel F shows the quantification of the 350-kDa 
cleavage product by densitometry in relation to the concentration of synthetic peptides (Mean ± 
SD, n=3, except for RYR). 
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4.4.3 Molecular modeling of VWF73 and RRYGEE complex 
Molecular modeling of VWF73 based on the crystal structure of the VWF-A2 domain28 
docked by the peptide RRYGEE using energy minimization algorithm (GROMACS4) 
revealed that the amino acid residues RRY fit into the pocket formed at the carboxyl 
terminal end of the VWF73 and Tyr-Met peptidyl bond, whereas the amino acid resides 
GEE reside outside of this pocket (Figure 4.2). These data suggest that direct engagement 
of the amino acid residues Arg659, Arg660 and Tyr661 with the central A2 domain of VWF 
may play a critical role for the efficient cleavage of VWF under both non-physiological 
and physiological conditions. 
 
 
Figure 4.2. Proposed model of VWF73 and spacer domain peptide complex. The α-helix and 
β-sheet are derived from the crystal structure of VWF-A2 domain. The C-terminal 9 amino acid 
residues of VWF73 peptide are indicated in blue. The sticks represent the amino acid residues 
(RRYGEE) found in the ADAMTS13 spacer domain. The complex between VWF73 and 
RRYGEE was modeled with an energy minimization algorithm with GROMACS4 software. The 
general model was carried out using PyMol software. Panel B is viewed at 325º rotation of the 
Panel A. The amino acid residues RRY make direct contact with the C-terminal 9 amino acid 
residues EAPDLVLQR in blue and Tyr-Met bond, whereas the residues GEE serve as a linker. 
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4.4.7 Molecular modeling of ADAMTS13-VWF specific interactions in the Cys-rich and 
Spacer domains 
To gain insight into the mechanisms underlying the enhanced activity of ADAMTS13 
variants, we performed molecular modeling using the existing crystal structure of 
ADAMTS13-DTCS fragment23 and VWF-A2 domain28. As shown, the spacer domain 
comprises ten β-sheets (i.e. β1-10), a pocket formed by various β sheets containing a 
cluster of hydrophobic residues (L591, F592, L637, F638, L668, and T669), and a ring 
formed by Y661 and Y665 lined by basic residues R568, R589, R660, and R636 (Figure 
4.3). This pocket appears to directly interact with the α6-helix (residues between D1653 
and R1668) in the central A2 domain of VWF. The hydrophobic residues in the A2 
domain presumably face the exosite 3 to make strong hydrophobic contacts in 
conjunction with some hydrogen bonds outside the pocket (Figure 4.3D). A substitution 
of R with K residue or Y with F residue or vice versa appears to alter the hydrophobicity 
in the exosite 3 (Figure 4.3C). The corresponding changes of hydropathy index were as 
follows: R→K: - 4.5 → -3.9 and Y→F: -1.3 → +2.8, thereby enhancing the interaction 
between VWF and ADAMTS13. Furthermore, a substitution of F592 with Y may open 
up the pocket even more, thereby better engaging substrate. There was also a 
corresponding backbone shift which appears to take place in the β2, β5, β6, and β9 sheets 
to compensate for the increased hydrophobicity. These changes allow greater engagement 
of the exosite 3 with A2 domain, particularly the amino acid residues between residues 
D1653 and R1668.  
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Figure 4.3. Modeling of ADAMTS13-spacer and VWF-A2 interaction. A. Surface 
representation of ADAMTS13-DTCS fragment; B. Close-up view of the hydrophobic cluster in 
the exosite of ADAMTS13 spacer domain. This pocket contains a cluster of hydrophobic residues 
(L591, F592, L637, P638, L668, T669, and ring of Y661 and Y665), lined by basic residues 
(R568, R589, R636, and R660) supported by 8 β sheets (i.e. β1, 2, 3, 6, 7, 8, 9, and 10). C. A 
substitution of these surface residues with those in yellow appears to increase hydrophobicity of 
this pocket. D. VWF-A2 (1653-1668) forms an amphipathic helix (α6). Here shown are the 
hydrophobic residues facing to the top and charged residues to the bottom. This amphipathic 
helix may govern specificity to the ADAMTS13-spacer exosite by inserting its hydrophobic side 
into the pocket. 
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4.4.5 Crystallization of ADAMTS13 
 
We conducted initial crystal screens for ADAMTS13 carried out by the hanging-drop 
vapor-diffusion method using Index Screen, Crystal Screen, SaltRx Screen, PEG/Ion 
Screen, Grid Screen MPD and Grid Screen Ammonium Sulfate kits (Hampton Research, 
Aliso Viejo, California, USA) at 4°C and 25°C. Crystals were monitored for precipitate 
and microcrystal growth under an inverted microscope. From this initial set of screens, 
we were able to obtain 6 potential hits from solutions 4 (A), 12 (B), 20 (C) of the Crystal 
Screen 1 kit and solutions 10 (D), 14 (E), and 23 (F) of the PEG/Ion Screen kit. We 
performed grid optimization screens using the initial conditions and we were able to 
consistently grow crystals at 25° for 6 conditions (Figure 4.4). Preliminary diffraction 
data for these crystals was negative, except for one condition (Condition D, 0.17 M 
Ammonium Sulfate, 0.23 M HEPES pH 7.0, 33% PEG 8000) which yielded a low-
resolution, 6.5Å broad diffraction pattern (Figure 4.5). This pattern could likely be 
attributed to the very thin, needle-like morphology of the crystals. 
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Figure 4.4. Crystals of human FL-ADAMTS13 grown by the hanging-drop method. (a) 
Microcrystals were initially obtained from solutions 4 (A), 12 (B), 20 (C) of the Crystal Screen 1 
kit and solutions 10 (D), 14 (E), and 23 (F) of the PEG/Ion Screen kit. The crystals were obtained 
using the optimized conditions. 
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Figure 4.5. Diffraction pattern obtained for human FL-ADAMTS13 crystals grown by the 
hanging-drop method (following optimization from Condition D). The diffraction pattern was 
obtained to a resolution of 6.54Å for needle-shaped crystals under the conditions 0.17 M 
Ammonium Sulfate, 0.23 M HEPES pH 7.0, 33% PEG 8000. 
 
Overall, we screened over 900 conditions, out of which we got ~26 putative hits. The 
specific conditions that yielded diffractable crystals (Condition F, Figure 4.6) were: 
0.18M Sodium citrate tribasic dihydrate pH~6, 17% (v/v) (+/-)-2-Methyl-2,4-pentanediol 
(MPD), 22% tert-Butanol pH 6.0. These crystals formed after ~4 weeks at 298K. 
This condition was the result of initial optimization from a hit containing 0.1M Sodium 
citrate tribasic dihydrate pH 5.6, 35% tert-Butanol, which yielded no crystals in the initial 
screens, but did yield a productive precipitate. We used PEG 4000, PEG 8000, and MPD 
as additives in subsequent screens. This set of crystals was the result of 4 optimization 
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screens after using MPD as an additive (higher concentration of salt, lower 
concentrations of precipitant). 
 
 
 
Figure 4.6. Crystals of human FL-ADAMTS13 grown by the hanging-drop method 
(Condition F). The conditions were 0.18M Sodium citrate tribasic dihydrate pH~6, 17% (v/v) 
(+/-)-2-Methyl-2,4-pentanediol (MPD), 22% tert-Butanol pH 6.0. These crystals formed after ~4 
weeks at 298K. This condition was the result of initial optimization from a hit containing 0.1M 
Sodium citrate tribasic dihydrate pH 5.6, 35% tert-Butanol, which yielded no crystals in the initial 
screens, but did yield a productive precipitate. 
 
 
4.4.6 Structure determination 
Data were collected (Figure 4.7) to the diffraction limit (2.2 Å) and the structure solved 
as described in Methods. An unbiased view of the electron density was obtained by 
solvent flattening and non-crystallographic symmetry averaging. The phases obtained by 
molecular replacement were improved and bias removed by symmetry averaging and 
solvent flattening. The structure agrees with that previously reported23. A summary of the 
crystallographic data and refinement statistics are presented in Table 4.1. 
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Figure 4.7. Diffraction patterns and Wilson plots obtained for human FL-ADAMTS13 
crystals grown by the hanging-drop method (following optimization from Condition F). The 
diffraction pattern (Panels A and C) was obtained to a resolution of 2.2Å for single crystals under 
the conditions 0.18M Sodium citrate tribasic dihydrate pH~6, 17% (v/v) (+/-)-2-Methyl-2,4-
pentanediol (MPD), 22% tert-Butanol pH 6.0. The Wilson plots (Panels B and D) shown are for 
these diffraction patterns obtained from two different crystals grown under the same conditions. 
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Table 4.1. Data Collection and Refinement Statistics 
Data Collection  
  Space group P212121 
  Cell dimensions  
     a, b, c (Å) 39.11, 55.88, 69.84 
     α, β, γ (°) 90, 90, 90 
  Wavelength (Å) 0.987 
  Resolution range (Å) 43.6-2.22 
  Total unique reflections 21,9687 
  Rmerge 0.069 
  l/σl 12.8 (4.7) 
  Completeness (%) 98.8 (85.6) 
  Redundancy 3.5 (3.3) 
  
Refinement  
  Maximum resolution (Å) 2.22 
  No. reflections 18,694 (7949) 
  Rwork/Rfree (%) 20.1/23.7 
  rmsd bond length (Å) 0.009 
  rmsd bond angle (°) 0.962 
  
 
Oddly, we were able to reproducibly acquire high resolution diffraction patterns (2-2.5Å) 
that encompassed the P212121 space group. This space group cannot accommodate a 
protein as large as FL-ADAMTS13. In addition, molecular replacement (MR) with 
ADAMTS13-DTCS did not yield a favorable solution. The PHASER output indicated 
that, rather than being 145 kDa, the product was more likely around 20-30 kDa. Using 
multiple iterations of MR, we were finally able to find a suitable solution using the 
structure of human ADAMTS1 catalytic domain and cysteine-rich/spacer domains (apo-
form, PDB code 2V4B). We later confirmed this by truncating the ADAMTS13-DTCS 
fragment to CS and performing MR. The determined boundaries of the solved structure 
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were from M432 (in TSP-1) to R670 (in Spa). The structure (Figure 4.8A) encompasses 8 
residues in the 1st TSP-1 repeat, in addition to the entire cysteine-rich domain (CA and 
CB) and the majority of the spacer domain. 
Our structure agrees very well (Table 4.2) with the analogous portion of the 
ADAMTS13-DTCS structure previously reported (RMSD = 0.02Å, 1817 atoms, 232 
residues). A region within the CA domain (Q478 – R528) does vary slightly from 
ADAMTS13-DTCS (RMSD = 0.08Å, 379 atoms, 51 residues), however there are no 
significant differences in structure other than a shift in the α4 helix from G479-C483 
(Figure 4.8B, Table 4.2). As with the ADAMTS13-DTCS structure, our structure shows 
5 intermolecular disulfide bonds in Cys, in addition to 2 free cysteine residues. 
 
 
 
Figure 4.8. Structure of ADAMTS13-CS and structural alignment with ADAMTS13-DTCS. 
Panel A. Ribbon structure of ADAMTS13-CS in stereo. Blue indicates the ADAMTS13-Cys 
domain, while red indicates the ADAMTS13-Spa domain. Disulfide bonds (and free cysteines are 
indicated in yellow. Panel B. Structural alignment of ADAMTS13-CS (red) with the analogous 
portion of the published ADAMTS13-DTCS23 structure (teal). The G479-C483 alpha helix is 
slightly shifted in ADAMTS13-CS. 
 
 
 
A B 
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Table 4.2. Structural alignment of ADAMTS13-CS and ADAMTS13-DTCS 
Region RMSD (Å) No. of atoms No. of residues 
M432-R670 0.02 1817 232 
Q478 – R528 0.08 379 51 
G479-C483 0.15 31 6 
    
 
4.5 Chapter Discussion 
The crystal structure of the ADAMTS13-DTCS fragment demonstrates that amino acid 
residues Arg659, Arg660, Tyr661, and Tyr665 form a surface loop facing the solvent (Figure 
4.2). This loop may directly interact with the central A2 domain, presumably the C-
terminal end of VWF73 peptide (Gly1660-Arg1668) as the deletion of this C-terminal end 
from the VWF73 peptide resulted in an approximately 20-fold reduction of the cleavage 
rates by wild-type ADAMTS13.13 Such a rate reduction appears to be similar to that 
after the deletion of ADAMTS13 spacer domain8,10.  
It remains to be elucidated, however, how ADAMTS13-Spa gains access to the central 
A2 domain of the UL-VWF polymers anchored on endothelial cells. The newly released 
UL-VWF polymers from human endothelial cells after histamine stimulation appeared to 
be highly susceptible to ADATMS13 whether in the presence25,26 or in the absence27 of 
fluid shear stress. Spa, particularly the residues Arg659, Arg660, and Tyr661, play a role in 
recognition of cell-bound UL-VWF polymers11.  
The importance of Spa, particularly the amino acid residues Arg659, Arg660, and Tyr661 in 
substrate recognition in vivo, is highlighted by the results of antibody mapping. Luken et. 
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al.28,29 have shown that anti-ADAMTS13 IgG isolated from several patients with 
acquired idiopathic TTP directly targets against the amino acid residues between Val657 
and Gly666, which contains the triple peptide (Arg-Arg-Tyr). However, the role of this 
triple peptide in substrate recognition does not undermine the importance of the other C-
terminal noncatalytic domains of ADAMTS13.  
For instance, the precise engagement of amino acid residues Arg349, Leu350, and Val352 in 
the disintegrin domain with VWF-A2 domain30 and interactions between the VWF-D4-
CK domain with the more distal C-terminal domains of ADAMTS1330 also may play a 
role for productive cleavage of multimeric VWF in solution under physiologically 
relevant conditions. The results from genetic studies in mice and humans may further 
support the role of more distal C-terminal domains for ADATMS13 function. 
We conclude that the amino acid residues Arg659, Arg660, and Tyr661 in the ADAMTS13 
spacer domain play a critical role in recognition and proteolytic cleavage of peptidyl 
substrates, soluble VWF, and cell-bound VWF polymers under both static and fluid shear 
conditions. The reduced proteolytic activity of the spacer mutants in many cases is 
associated with the impaired binding interactions with the central A2 domain of VWF. 
Our findings may provide novel insight into the structure-function relationship of 
ADAMTS13 and shed some light on the pathogenesis of TTP and perhaps other arterial 
thrombotic disorders related to compromised VWF proteolysis by ADAMTS13. 
In the effort to crystallize full-length ADAMTS13, we were able to obtain a high 
resolution structure of the ADMTS13-CS fragment, presumably a product of autolysis 
under the crystallization conditions (0.18M Sodium citrate tribasic dihydrate, 17% (v/v) 
(+/-)-2-Methyl-2,4-pentanediol (MPD), 22% tert-Butanol pH 6.0). The nature of this 
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autolysis, which is reproducible under these conditions, is unknown. There is evidence31 
that pH can affect the activity of ADAMTS13, however there are no substantial reports 
on autolysis by the Metalloprotease domain. We will probe the exact conditions under 
which autolysis occurs to remedy this issue. 
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5.1 Overview 
Proteolytic cleavage of ultra large von Willebrand factor (ULVWF) released from 
endothelial cells by ADAMTS13 metalloprotease is critical for maintaining normal 
hemostasis. However, the effect of infusing ADAMTS13 on thrombus composition 
remains poorly understood. In this study, we determined the morphology and 
composition of thrombi formed in carotid arteries after topical application of FeCl3 in 
Adamts13-/- mice receiving PBS, recombinant human full- length ADAMTS13 (FL) 
and carboxyl-terminal truncated variant after spacer domain (S), using scanning electron 
microscopy and quantitative image analysis. We showed that in Adamts13-/- mice 5 min 
after FeCl3 injury, formed arterial thrombi were comprised ~39% platelets, ~26% red 
blood cells, and ~35% fibrin. The arterial thrombi in these mice were structurally 
deformed. An infusion of recombinant FL (final concentration of 10 nM) significantly 
reduced the accumulation of platelets (~18%) but increased the fibrin network (57%) 
without affecting the composition of red blood cells (~25%) in the arterial thrombi 
formed at the same time point after FeCl3 injury. Similar effects on the morphology and 
composition of FeCl3-induced arterial thrombi were observed after infusion of 
recombinant S (10 nM) into Adamts13-/- mice.   
Kinetic analysis showed that there was a decrease in platelet accumulation over the time 
of 30 min during thrombus formation with a slight increase in accumulation of red blood 
cells and formation of fibrin in Adamts13-/- mice. But, the infusion of recombinant FL 
and S into Adamts13-/- mice restored the kinetics of platelet/red blood cell accumulation 
and fibrin formation to those observed in wild-type mice. Our findings, revealing the 
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apparent difference in thrombus composition, provide novel insight into the mechanism 
of ADAMTS13 function in vivo, which may shed more light on the pathogenesis of 
thrombotic thrombocytopenic purpura and other arterial thrombotic disorders associated 
with deficiency of plasma ADAMTS13 activity. 
 
5.2 Introduction 
Studies have shown that the cleavage of endothelial ULVWF occurs very rapidly with4 or 
without5 fluid shear stress, suggesting that newly-released ULVWF on endothelial cell 
surface may be in its “open” conformation. However, the VWF cleaved from endothelial 
cells by ADAMTS13 remains ultra-large by multimer analysis4, suggesting that further 
proteolytic processing of these released VWF multimers, likely to occur in 
microvasculature, may be necessary to reduce the size.  
Exposure of the soluble VWF to high shear stress or denaturants may open up the binding 
and cleavage sites, which are normally buried under the β-sheet in the central A2 
domain7. Moreover, binding of factor VIII (FVIII)8, platelets9 or both10 to soluble VWF 
also increases its cleavage by ADAMTS13 under shear stress. These results suggest a 
cofactor-dependent mechanism regulating VWF proteolysis by ADAMTS13 under 
physiologically relevant conditions.  
In addition, as mentioned previously, the role of the C-terminal domains of ADAMTS13 
in vivo has long been controversial. For instance, a study from our lab reported that a C-
terminally truncated ADAMTS13 variant after the spacer domain expressed by an in 
utero injection of lentiviral vector eliminated plasma ULVWF and inhibited ferric 
chloride (FeCl3)–induced arterial occlusion in the carotid artery of Adamts13-/- mice17, 
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while another study18 showed that a naturally occurring murine ADAMTS13 variant 
truncated after the sixth TSP1 repeat (ADAMTS13S/S) was less efficacious than full-
length ADAMTS13 in inhibiting FeCl3-induced thrombosis in the mesenteric arteriole18. 
Finally, it has been reported19 that a recombinant murine ADAMTS13 variant truncated 
after the eighth TSP1 repeat, infused into Adamts13-/- mice, was not able to cleave newly 
released ULVWF/VWF strings on the endothelial cells in the mesenteric 
arterioles/venules19. 
These discrepant results prompted our lab to systematically investigate the structure-
function relationship of ADAMTS13 in vivo using a recombinant protein strategy and a 
murine thrombosis model20. Using recombinant proteins and a murine model, we 
demonstrated that an ADAMTS13 variant truncated after either the eighth 
thrombospondin type 1 repeat or the spacer domain inhibits ferric chloride–induced 
arterial thrombosis in Adamts13-/- mice with efficacy similar to that of full-length 
ADAMTS13, suggesting that the amino terminus of ADAMTS13, specifically the 
variable region of the spacer domain, is crucial for modulation of arterial thromboses 
under physiological conditions20. 
Even with these results, the effect of infusing ADAMTS13 or ADAMTS13 variants on 
thrombus formation and overall thrombus composition is poorly understood. 
Understanding of this process can elucidate possible unknown functions of ADAMTS13 
in thrombus formation and inform researchers about the usefulness of soluble 
ADAMTS13 as a potential therapy for TTP and other arterial thrombotic disorders.  
In this study, we examine thrombi after FeCl3 injury in Adamts13-/- mice before and after 
injection of FL-ADAMTS13 and variants, to determine: 1) the time-dependent 
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composition of thrombi (time after injury); 2) the differential composition at the head 
and tail of the thrombus; and 3) the change in composition with reconstitution of normal 
thrombosis. We show that infusion of recombinant FL-ADAMTS13 and an 
ADAMTS13 variant truncated after either the eighth thrombospondin type 1 repeat into 
Adamts13-/- mice restored the kinetics of platelet/red blood cell accumulation and fibrin 
formation to those observed in wild-type mice. Our findings reveal the effect of 
ADAMTS13 deficiency on thrombus composition and thrombus formation dynamics 
over time, providing novel insight into the mechanism of ADAMTS13 function in vivo. 
These results may further elucidate the pathogenesis of thrombotic thrombocytopenic 
purpura and other arterial thrombotic disorders. 
 
5.3 Materials and Methods 
5.3.1 Preparation of carotid artery samples and fixation for microscopy 
C57BL/6 Mice at 2 to 4 months of age were anesthetized with Nembutal. The right 
carotid artery was exposed by blunt dissection. PBS (100 µL) alone or PBS containing 
recombinant human ADAMTS13 and variants (final concentration, 10 nmol/L) was 
injected into mice via the retro-orbital plexus. The amount of ADAMTS13 or variants 
injected was determined based on the body weight and blood volume of mice to achieve 
physiological plasma concentrations (~10 nmol/L). The ADAMTS13, variant, or PBS 
were infused via a jugular vein into Adamts13-/-  mice (~1 ml blood for ~14 g body 
weight). This resulted in final concentrations of ~10 nmol/L ADAMTS13 in mouse 
circulation. In the indicated number of minutes after protein infusion, injury was induced 
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by exposing the carotid artery to 10% ferric chloride (FeCl3) (anhydrous) soaked on a 
piece of filter paper (1x2 mm) for 2 minutes.20 The filter paper was then removed, and 
the artery sections were flushed with PBS and fixed in 2.5% glutaraldehyde in 0.1M 
Sodium Cacodylate buffer pH 7.4. 
 
Figure 5.1. Schematic showing preparation of carotid artery samples in C57BL/6 mice. 
 
5.3.2 Immunofluorescent microscopy of carotid artery samples 
After being washed with phosphate-buffered saline (PBS), arteries were fixed with 1% 
paraformaldehyde in PBS (non-permeabilized) for 10 min. The arteries were then flash-
frozen in OCT medium (Tissue-Tek) and sectioned in a cryostat (5-µm sections) at           
-25°C. Sections were placed onto microscope slides and allowed to adhere at room 
temperature. The sections were blocked with 2.5% bovine serum albumin (BSA) in PBS 
for 30 min and incubated with a primary antibody (monoclonal anti-VWF, polyclonal 
anti fibrinogen, monoclonal anti-GP1b, or polyclonal anti-CD34) (1:200) for 2 h at 22°C, 
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followed by a fluorescein-conjugated secondary antibody diluted in 0.5% BSA in PBS 
for 1 h. The sections were then incubated with Alexa Fluor® 647 conjugated transferrin 
(Invitrogen) (1:500) for 10 min, and mounted with medium containing 4’,6 diamidino-2-
phenylindole (DAPI) (1:5) (Vector Lab, Burlingame, CA, USA) after three washes with 
PBS. The fluorescent signals were determined under a multi-color fluorescent 
microscope. The images were obtained using SPORTadvanced software (Sterling 
Heights, MI) at magnifications of 100X and 600X. 
 
5.3.3 Scanning electron microscopy of carotid artery samples 
Sample fixation, dehydration, and preparation of samples were performed according to 
the method of Weisel and Nagaswami21. High definition photographs (3000X 
magnification) were obtained using a Philips/FEI XL20 scanning electron microscope 
(4nm resolution) (FEI, Hillsboro, OR, USA) at 10 KV accelerating voltage. To control 
for composition heterogeneity in the analysis of the thrombus, we examined several areas 
(at least 12 according to a grid and the size of the thrombus) for each thrombus, in an 
unbiased manner at low magnification and at least a dozen digital images were taken at 
the highest resolution. 
 
5.3.4 Quantitative analysis of micrographs by FOAMS (Fast Object Acquisition and 
Measurement System) 
Image processing analysis was carried out by a modified version of FOAMS (Fast Object 
Acquisition and Measurement System), which is a Matlab®-based program initially 
designed to help geologists wishing to initiate in vesicle texture studies22,23. We have 
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modified the FOAMS program to perform size analysis on 1 µm2 grid sections of SEM 
micrographs, based on the established method by Silvain et. al.24. Analysis of the size 
characteristics of each of these sections, based on grayscale representation of analyzable 
objects, is cumulatively expressed as a total quantitative measure. 
For Adamts13-/- mice thrombi, images were processed by Adobe Photoshop® for 
preparation for size analysis. Briefly, the required input for FOAMS is a set of images 
with distinct shades of gray corresponding to various analyzable objects (bubbles, 
crystals, etc.). Shades of gray have values between 0 and 255 (called Digital Numbers, or 
DN). For instance, all “bubble” objects might have a DN value of 0 (black) and the other 
objects intermediate values until white (DN = 255)22. Once images were processed, they 
were input into the FOAMS program, which superimposed a grid with 1 µm2 squares and 
identified and analyzed the size of objects (platelets, red blood cells, fibrin, and 
macrophages) in each grid section based on the DN. 
 
5.3.5 Focused ion beam milling and scanning-transmission electron microscopy of fixed 
artery sections 
SEM/SED/STEM was performed using a Strata DB235 Focused Ion Beam (FEI) during 
FIB milling. An electron beam at 20 kV was used to do the initial "trench" digging, and 2 
kV at a slight tilt for the final thinning. After excising ~100 nm thick FIB sections with a 
needle and mounting them on carbon grids, they were visualized by a JEOL 2010 TEM at 
60 kV. 
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5.4 Results 
5.4.1 Scanning electron microscopy indicates differences in the morphology and 
composition of WT and Adamts13-/- mice arterial thrombi 
In order to determine the necessary components of arterial thrombi to track, we used 
immunofluorescent microscopy to observe the predominant species of molecules 
(platelets, fibrin, red blood cells, macrophages, and VWF) in extracted arterial thrombi. 
After using antibodies to probe all of the aforementioned components, we found that we 
were able to detect fibrin and platelets reproducibly enough to serve as a standard for 
measuring the thrombus composition (Figure 5.2). In subsequent scanning electron 
microscopy images we were also able to reproducibly identify a large number of red 
blood cells. Thus, we determined that the optimal components for quantifying arterial 
thrombus composition would be fibrin, platelet, and red blood cell content. 
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Figure 5.2. Immunofluorescent staining of carotid artery sections of WT mice after FeCl3-
induced thrombosis. Hematoxylin-Eosin staining of a frozen carotid artery section showing 
vessel walls and thrombi of wild-type C57BL/6 mice 30 minutes after FeCl3 induced thrombosis 
(Panel A). Immunofluorescent staining of a different section of the same frozen carotid artery of 
wild-type mice 30 minutes after FeCl3 induced thrombosis (Panel B). Blue dots indicate nuclei in 
vessels stained by DAPI. Also shown are Fibrin (red), platelet-specific CD41 (green), and merged 
images. 
 
In this study, we also determined the morphology and composition of thrombi formed 
using scanning electron microscopy and quantitative image analysis in carotid arteries 
after topical application of FeCl3 in Adamts13-/- mice receiving PBS, recombinant human 
full-length ADAMTS13 (FL) and carboxyl-terminal truncated variant after spacer 
domain (S). We showed that in Adamts13-/- mice 5 minutes after FeCl3 injury, formed 
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arterial thrombi that were very platelet- and red blood cell-rich (Figure 5.3B and D), 
compared to the thrombi of wild-type mice 5 minutes after FeCl3 injury (Figure 5.3A and 
C). The arterial thrombi in these mice were deformed ultrastructurally (Figure 5.3D) 
compared to the thrombi of wild-type mice (Figure 5.3C).  
 
 
Figure 5.3. Scanning electron microscopy analysis of thrombi from the carotid arteries of 
Adamts13-/- mice after FeCl3-induced arterial thrombosis. Carotid artery sections showing 
vessel walls and thrombi of wild-type C57BL/6 mice 0 and 30 minutes after FeCl3 induced 
thrombosis (Panels A and C). Carotid artery sections showing vessel walls and thrombi of 
Adamts13-/- C57BL/6 mice 0 and 30 minutes after FeCl3 induced thrombosis (Panels B and D). 
The thrombi were fixed, processed and examined on a FEI Quanta FEG SEM.  
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5.4.2 Kinetic analysis indicates that infusion of FL-ADAMTS13 or C-terminal truncated 
ADAMTS13 variant restores the kinetics of platelet/red blood cell accumulation and 
fibrin formation 
Infusion of recombinant FL (final concentration of 10 nM) significantly reduced the 
accumulation of platelets (~18%) but increased the formation of fibrin network (57%) 
without affecting the composition of red blood cells (~25%) in the arterial thrombi at the 
same time point after FeCl3 injury (Figure 5.4). 
A similar effect on the morphology and composition of FeCl3-induced arterial thrombi 
was observed after infusion of recombinant S (10 nM) into Adamts13-/- mice. Kinetic 
analysis showed that there was a decrease in platelet accumulation over a time of 30 min 
following FeCl3 injury, with a slight increase in accumulation of red blood cells and 
fibrin formation in Adamts13-/- mice. Infusion of recombinant FL and S into Adamts13-/- 
mice restored the kinetics of platelet/red blood cell accumulation and fibrin formation to 
those observed in wild-type mice (Figure 5.4). 
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Figure 5.4. Time-dependent thrombus formation by scanning electron microscopy. Carotid 
artery sections from C57BL/6 mice were removed the indicated number of minutes after topical 
application of 10% FeCl3 for 5 min under a fluorescent microscope. Fully-formed thrombi were 
exposed in the carotid artery of wild type mice, Adamts13-/- mice receiving PBS, full-length 
ADAMTS-13 (FL-A13), and MDTCS, 10 nM. The thrombi were fixed, processed and examined 
on a FEI Quanta FEG SEM. The thrombus composition from wild-type, Adamts13-/- mice 
receiving PBS, FL, and S (10 nM) was quantified (n=15) by the Fast Object Acquisition and 
Measurement System, which is a Matlab®-based program to perform size analysis on 1 µm2 grid 
sections of SEM micrographs. Analysis of the size characteristics of each of these sections, based 
on grayscale representation of analyzable objects, was cumulatively expressed as a total 
quantitative measurement. The kinetic data of fibrin, platelets and red blood cells are shown. 
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5.4.3 An apparent increase in platelet density at the tail of thrombi in Adamts13-/- mice is 
corrected by infusion of FL-ADAMTS13 or C-terminal truncated ADAMTS13 variant 
Using Focused Ion Beam milling, we were able to generate sections of the thrombi 
(Figure 5.5A) which spanned from the head to the tail, allowing analysis of differential 
composition in the primary areas. Preliminary analysis indicates an apparent increase in 
platelet density at the tail of thrombi in Adamts13-/- mice at 10 min after FeCl3 injury, 
while there was no apparent difference in composition at the head (Figure 5.5B). 
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Figure 5.5. Focused Ion Beam milling with subsequent EM visualization of arterial 
thrombus sections. Carotid artery sections from mice were removed 30 min after topical 
application of 10% FeCl3 under a fluorescent microscope. Panel A shows a representative 
SEM/SED/STEM image of mouse artery surface during FIB milling. An electron beam at 20 kV 
was used to do the initial "trench" digging, and 2 kV at a slight tilt for the final thinning. Trenches 
were dug every 100 microns from the point that was marked as the site of injury. Panel B shows 
the images of excising FIB sections with a needle and mounting them on carbon grids, visualized 
by a JEOL 2010 TEM at 60 kV. Sections at 0, 100, and 300 microns from the marked site of 
injury are shown. Mostly platelets are seen, with occasional red blood cells and macrophages. 
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5.5 Chapter Discussion 
We have seen that ADAMTS-13-MDTCS appears to be sufficient for proteolytic 
cleavage of ULVWF in vivo; thereby offering systemic protection of mice against FeCl3 
induced arterial thrombosis in the carotid artery. Imaging analysis indicates that normal 
thrombi appear to be well-formed and fibrin-rich, whereas Adamts13-/- C57BL/6 mice 
exhibit thrombi with multiple malformations and areas enriched with platelets and 
erythrocytes (less apparent fibrin). Imaging analysis indicates that normal thrombi appear 
to be well-formed and fibrin-rich, whereas Adamts13-/- C57BL/6 mice exhibit thrombi 
with multiple malformations and areas enriched with platelets and erythrocytes (less 
apparent fibrin). Preliminary study of the formation dynamics as a function of time and 
with infusion of FL-ADAMTS13 and MDTCS indicates an apparent reconstitution of the 
normal thrombus composition upon full formation of the thrombus, however it appears 
that the early stages of formation differ from that of wild-type mice. Using focused ion 
beam (FIB) milling, we study the differential composition of the thrombi at the head and 
tail, informing us about the potential for embolism or other complications.  
The FIB milling technique, although potentially very helpful, is wrought with technical 
difficulties. Quantitation of the acquired TEM images is very difficult because the 
morphology of the platelets, fibrin, and red blood cells is distorted in the images. This is 
likely due to a well-known phenomenon where a thin “film” is left by the laser trench 
digging on the excised section. This film could potentially interfere with subsequent 
visualization. We endeavor to use live confocal microscopic imaging to determine the 
extent of malformation of the arterial thrombi in Adamts13-/- mice, and to determine 
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whether infusion of ADAMTS13 or variants has a differential effect on the thrombus 
composition at different areas of the thrombus. 
Our findings, revealing the apparent difference in thrombus composition, provide novel 
insight into the mechanism of ADAMTS13 function in vivo, which may shed more light 
on the pathogenesis of thrombotic thrombocytopenic purpura and other arterial 
thrombotic disorders associated with deficiency of plasma ADAMTS13 activity. 
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CHAPTER 6: SUMMARY, GENERAL DISCUSSION, AND FUTURE 
PLANS 
 
6.1 Summary 
The regulation of proteolytic cleavage of multimeric VWF by ADAMTS13 under 
physiological conditions remains an unanswered question in the field. It is currently 
unknown how ADAMTS13 preferentially cleaves UL-VWF under flow shear stress to 
generate sizes of VWF multimers that normally circulate in plasma, ranging from 500 
kDa to 2,000 kDa1. Several hypotheses have been proposed to explain this phenomenon: 
1) modulation of cleavage by high fluid shear stress; 2) binding of platelets or protein 
cofactors to VWF2; 3) the exosite interactions between VWF and ADAMTS133. 
Multimeric VWF is highly sensitive to shear stresses. At a critical shear stress of 35 ± 3.5 
dynes/cm2, VWF changes its conformation from globular to elongated in shape, which 
has been shown by atomic force microscopy4. Therefore, it is conceivable that the larger 
the VWF multimers, the more sensitive they are to deformation by high shear stress. The 
work of this thesis has demonstrated that FVIII and platelets cooperatively accelerate 
proteolytic cleavage of soluble VWF by ADAMTS13 through an alteration of VWF 
substrate conformation under physiologically relevant fluid shear stresses. We have 
established the critical role of the VWF propeptide and FVIII- and platelet-binding 
domains of VWF in regulating proteolysis of VWF by ADAMTS13 under 
physiologically relevant shear stress using type 2N VWF mutants. Through site-directed 
mutagenesis, kinetic analyses, and peptide inhibition assays we have identified a 
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substrate-binding exosite encompassing ADAMTS13 residues Arg659, Arg660 and Tyr661 
that exhibits an important role in proteolytic cleavage of VWF under both non-
physiological and physiological conditions. In addition, modification of an exosite 
binding region of ADAMTS13 yielded ADAMTS13 variants with reduced inhibition by 
autoantibodies and enhanced specific activity. Finally, we have demonstrated that 
infusion of an ADAMTS13 variant, truncated after the Spacer domain, can restore 
thrombus composition and the kinetics of platelet and fibrin accumulation in Adamts13-/- 
mice. Together, these results suggest an important physiological role of cofactor binding 
to VWF and VWF interactions with ADAMTS13 exosites in regulating ADAMTS13 
function in hemostasis, in addition to shear-induced unfolding of VWF. 
 
6.2 General Discussion 
6.2.1 VWF binding to cofactors, and subsequent increased susceptibility to ADAMTS13 
cleavage, is an autoregulatory mechanism 
The results presented in Chapter 2 and Chapter 3 suggest that binding of FVIII or 
platelets to VWF may facilitate the deformation of VWF substrate by altering the 
domain-domain interactions among the various VWF subunits. This global 
conformational change appears to be sufficient to increase VWF proteolysis. FVIII and 
platelets, thus, serve as physiological cofactors for VWF proteolysis by ADAMTS13, 
whose purpose is to lower the free energy required for conversion of substrate 
(multimeric VWF) to product (cleaved VWF) (Figure 6.1). Together, these findings, both 
from the investigation of the mutant cofactor (i.e. FVIII) and the mutant substrate (i.e. 
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VWF), underscore the critical role of FVIII-VWF interactions in regulating proteolysis of 
VWF under physiologically relevant conditions. 
 
Figure 6.1. Schematic showing the cofactor effect of FVIII and platelets in VWF proteolysis 
by ADAMTS13. FVIII and platelets serve as physiological cofactors for VWF proteolysis 
by ADAMTS13, whose purpose is to lower the free energy required for conversion of 
substrate (multimeric VWF) to product (cleaved VWF). The reaction coordinate to the 
right indicates that the large free energy barrier shown can be overcome by using 
cofactors. FVIII and platelets overcome this free energy barrier by mechanical means, 
altering VWF conformation, making the Tyr1605-Met1606 cleavage bond more easily 
accessible by ADAMTS13. 
 
 
The enhancing effect of FVIII and platelets on VWF proteolysis appears to depend on the 
specific binding interactions between the light chain of FVIII and the VWF-D’D3 
domain, and the interactions between platelet GP1bα receptor and the VWF-A1 domain. 
However, it remains to be determined how binding of FVIII and platelets to soluble VWF 
results in an increased cleavage of VWF by ADAMTS13 under fluid shear stress. The 
binding of FVIII to the VWF-D’D3 domain may cause a large scale conformational 
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change of VWF multimers, such as pulling away the D’D3 domain from its neighboring 
A1 or A2 domain in the presence of fluid shear stress. Under physiological conditions, 
plasma FVIII concentration is quite low, approximately 0.5-1 nM11,12, whereas plasma 
VWF (subunit) concentration is approximately 50 nM12, suggesting that approximately 
one FVIII is bound to every 50 VWF subunits (equal to ½ to one UL-VWF multimer). 
Similarly, less than 3 platelets may be bound to every 1,000 VWF subunits12. The 
binding of platelets or even soluble GP1bα to the VWF-A1 domain may further alter the 
domain-domain interactions of multimeric VWF. This was shown to occur even after 
VWF or A1A2A3 or A1A2 has been pre-denatured under static conditions13.  
Moreover, the binding of two or more platelets on either side of the cleavage bond of 
VWF multimers may dramatically increase the peak force exerted on the central A2 
domain. For instance, in the presence of 20 dynes/cm2 shear force, the predicted peak 
force soluble VWF multimers experience ranges from 0.2 to 0.8 pN14 in the absence of 
platelets. The peak force increases to ~390 pN when two or more platelets are bound at 
either side of the scissile bond14. This is the amount of shear stress if applied directly to a 
VWF fragment such as the A1A2A3 or A2 domain in which both ends are attached to a 
solid surface10,14. 
To investigate how the FVIII level in plasma modulates the size of VWF multimers, our 
lab has performed some studies to reconstitute plasma FVIII levels in fVIII-/- mice15. The 
results showed that the reconstitution of plasma FVIII by overexpressing human FVIII 
abrogates a massive accumulation of high molecular weight VWF multimers released 
from endothelial cells triggered by hydrodynamic injection. Accordingly, increased VWF 
antigen level in hydrodynamic injection groups drop to the basal level similar to that in 
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fVIII-/- mice without hydrodynamic injection15. These findings further suggest that 
binding of FVIII to VWF might alter the rate of processing of VWF by ADAMTS13.  
However, it is also of importance to note that there is a minor discrepancy between the 
biochemical observations presented in this thesis and the aforementioned animal studies. 
In the in vitro studies, the presence of FVIII leads to a selective removal of the larger 
multimers of VWF that coincides with the increase of the smaller ones. The diminished 
high molecular weight VWF multimers are due to ADAMTS13-mediated proteolysis. 
However, the animal study shows the disappearance of the accumulated high molecular 
weight VWF multimers in plasma by hydrodynamic injection of FVIII do not 
correspondingly increase the smaller multimers15. It is speculated that the removal of 
high molecular weight VWF multimers is caused either by an enhanced proteolytic 
cleavage by ADAMTS13 and/or by an increase the clearance of the high molecular 
weight VWF multimers. This peculiar occurrence underscores the dichotomy that exists 
between FVIII and VWF when they are bound together: on one hand, FVIII stability in 
plasma is contingent upon binding to VWF, while on the other hand, VWF is protected 
from clearance, and even conformationally altered, in the presence of FVIII. Given that 
one FVIII molecule binds per every ~50 VWF subunits, there remains a perplexing issue 
regarding how FVIII can cause such a drastic conformational change to the A2 domains 
of multiple VWF monomers in a multimer. 
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6.2.2 The collection of data about ADAMTS13 exosites informs the role of shear stress in 
the dynamic interactions taking place between ADAMTS13 and VWF 
The results of Chapter 4 indicate an identified substrate exosite in Spa. These exosites 
work by effectively shifting the equilibrium of a reaction towards product conversion by 
utilizing long-range interactions with the substrate (Figure 6.2). This work adds to the 
wealth of knowledge about exosites in Spa3, Cys6, and Dis7 that have been previously 
identified. In vitro studies have demonstrated that even under high shear stress, the 
proteolytic cleavage of multimeric VWF in solution by ADAMTS13 is rather slow and 
inefficient. This is because VWF in solution adopts a globular conformation with various 
subunits held together by weak interactions5. Such a globular VWF is neither active for 
ligand binding (such as interacting with platelet GP1bα)6 nor sensitive to ADAMTS13 
proteolysis7, although the C-terminus of globular VWF (the D4-CK domain) is able to 
interact with the C-terminal TSP1 5-8 repeats of ADAMTS13 in the absence of 
denaturants or shear stress7,8. Such an initial contact may be critical for the subsequent 
interaction between the exposed VWF-A2 domain and the proximal C-terminal domains 
of ADAMTS13, leading to proteolytic cleavage of multimeric VWF under fluid shear 
stress. A disruption of these C-terminal VWF and C-terminal ADAMTS13 interactions 
inhibits VWF proteolysis under these conditions7,8. High fluid shear stress results in 
conformational changes of VWF multimers and opens up the binding sites and cleavage 
bond in the central A2 domain7,8,9 normally buried  in the hydrophobic core of the native 
VWF-A2 domain (Figure 6.3). 
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Figure 6.2. Schematic showing the substrate exosite effect on enzymatic activity, as seen 
with ADAMTS13 and VWF. Interactions between VWF and several ADAMTS13 
exosites—substrate binding sites distant from the active site—enhance protease activity. 
This exosite binding, indicated in the schematic as P1-S1, P2-S2, and P3-S3, supports the 
main substrate interaction with the enzyme active site. This serves to shift the equilibrium 
to product formation because the substrate can engage the active site more intimately. 
Several ADAMTS13 domains interact with distinct sequences on an extended segment of 
the VWF-A2 domain. Each of these interactions is relatively weak, but together they 
cooperate to enhance ADAMTS13 substrate specificity, which is critical for hemostasis. 
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Figure 6.3. Proposed model for in vivo cleavage of VWF by ADAMTS13. Studies have shown 
that the C-terminus of globular VWF (the D4-CK domain) is able to interact with the C-terminal 
TSP1 5-8 repeats of ADAMTS13 in the absence of denaturants or shear stress7,8. High fluid 
shear stress results in conformational changes of VWF multimers and opens up the binding sites 
and cleavage bond in the central A2 domain7,8,9 normally buried  in the hydrophobic core of the 
native VWF-A2 domain. More distinct exosite interactions occur with the Cys-rich, Spa, and Dis 
domains that ultimately govern the specificity of ADAMTS13 for VWF and orient the Met active 
site proximal to the Tyr1605-Met1606 cleavage bond. This results in efficient cleavage of VWF 
by ADAMTS13 only at sites where VWF has an optimal conformation (likely at the vessel 
walls). 
 
6.2.3 The co-existence of ADAMTS13 substrate exosites and inhibitory autoantibody 
binding sites suggests a flexibility in ADAMTS13 structure that has been utilized by 
nature 
In Chapter 4, it was shown through peptide inhibition studies and molecular modeling 
that amino acid residues Arg
659
, Arg
660
 and Tyr
661
 (or RRY) play an important role in 
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proteolytic cleavage of various substrates under both non-physiological and physiological 
conditions. This site, which is commonly thought to be a major antigenic epitope for the 
majority of TTP patient autoantibodies targeting the Cys-rich and Spa domains26, is very 
surface-exposed. It follows that this will likely be a site of binding to VWF because these 
residues, which reside on a loop, appear to readily interact with the α6 helix of the VWF 
A2 domain, as shown by modeling studies (Figure 6.4). It still remains perplexing, 
however, how this region can be a major antigenic epitope, given the strong interaction 
between ADAMTS13 and VWF. Inhibition studies26 have suggested that the inhibiting 
activity of these autoantibodies may not be entirely competitive. It becomes much more 
imperative that, instead of defining epitope regions for autoantibody binding, that we 
discover, at an amino acid level, the critical interactions that take place between the 
antibodies and ADAMTS13 to gain insight into whether there is a unique type of 
allostery taking place when there is a putative ADAMTS13-VWF-antibody complex that 
forms. 
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Figure 6.4. Model of ADAMTS13 MDTCS showing surface-exposed exosites. Adapted from 
Akiyama et. al.27 MDTCS was built from the existing DTCS crystal structure docked onto a 
homology-modeled ADAMTS13 metalloprotease domain, based on the structures of 
ADAMTS117 (PDB: 2V4B), ADAMTS418,19 (PDB: 3B2Z), and ADAMTS518,19 (PDB: 3B8Z). 
Sequence alignment (Panel A) indicates sequence identities of22.8% (ADAMTS1), 23.5% 
(ADAMTS4) and 22.0% (ADAMTS5). MODELLER v 9.11, run by the UCSF Chimera GUI 
(Graphical User Interface) was used to generate the initial model. Dead-end elimination was used 
to optimize orientation of all side chains and polar hydrogens, and optimized bond geometry by 
energy minimization with GROMACS v 4.5.5, using the GROMOS96 43a1 force field. The 
model of MDTCS (Panel B) indicates the ADAMTS13 exosites identified to date, showing that 
they are all surface-exposed. The exosite containing Arg
659
, Arg
660
 and Tyr
661
 is shown in purple. 
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In addition, Chapter 4 showed that modification of an exosite in Spa generated 
ADAMTS13 variants with reduced inhibition by anti-ADAMTS13 IgGs while preserving 
or enhancing specific activity. Molecular modeling using the existing crystal structure of 
ADAMTS13-DTCS fragment and VWF-A2 domain indicated a shift in hydrophobicity 
and subsequent opening of the VWF-A2 binding pocket on the ADAMTS13 spacer 
domain, potentially resulting in increased hydrophobic interactions in the pocket and 
hydrogen bonding on the exterior of the pocket. Despite the polyclonal nature of anti-
ADAMTS13 IgGs, the inhibitory activity appears to be largely mediated through binding 
to Spa, as the mutations in this region dramatically reduced binding and inhibition by 
patients’ autoantibodies. Although it was not previously noted in the Chapter, a level of 
concern has been raised about the exact nature of the gain-of-function mutants’ ability to 
accelerate VWF proteolysis. Preliminary binding studies have shown that the binding of 
these ADAMTS13 variants (particularly M4 and M5) is almost unchanged compared to 
wild-type ADAMTS13, which directly contradicts the modeling analysis mentioned 
above. I reason that modification of exosites in Spa can have effects on other exosites in 
the region to alter the specificity of binding altogether. This has potential usefulness 
when trying to intelligently design gain-of-function enzymes using the same approach 
with other potential exosites. Indeed, if we can decipher the exact relationship between 
changes in exosites proximal to each other, we could embark upon a process of de novo 
design, which would allow for us to evade a specific panel of patient antibodies. 
Furthermore, the crystallization, screening, data collection, and structure determination 
presented in Chapter 4 for an autolysis product of ADAMTS13, the ADAMTS13-CS 
fragment, provides the basis for beginning crystallization studies of complexes to probe 
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amino acid specificity of ADAMTS13 exosite binding with VWF and autoantibody 
recognition. The present structure suggests a linear correspondence between the 
ADAMTS13 domains and their interaction sites in the A2 domain of VWF. We suggest 
that Spa contains an exosite that primarily determines catalytic efficiency by interacting 
with α6 of the VWF A2 domain3. Other studies have identified 3 other VWF segments 
that interact with the MD, T1, and C domains of ADAMTS1316, suggesting that the 
catalytic cleft, plus exosite binding sites, make cooperative, modular contacts along the 
length of VWF. Furthermore, the M domains of ADAMTS4 and ADAMTS5 do not 
retain specific catalytic activity. The inclusion of the proximal C-terminal domains 
enhances their aggrecanase activity, suggesting that these ADAMTSs function through 
multiple exosites17,18,19, as observed in the ADAMTS13-VWF system. It is, thus, 
reasonable to conclude that, much like VWF structure in the presence of varying 
environments of shear stress, ADAMTS13 can adopt multiple configurations to 
accommodate a multitude of potential substrate conformations. 
6.2.4 The observed autolysis of ADAMTS13 may point to other autoregulatory functions 
of ADAMTS13 
Our efforts to crystallize full-length ADAMTS13 in Chapter 4 yielded a high resolution 
structure of the ADMTS13-CS fragment, presumably a product of autolysis under the 
crystallization conditions. The nature of this autolysis, which is reproducible under these 
conditions, is unknown. The lack of substantial reports on autolysis by Met presents the 
possibility for an intriguing and potentially very informative set of experiments. The 
autolysis appears to occur under conditions of low pH and high ionic strength.  
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It is well known that intense exercise can result in acidosis, or low pH. The propensity of 
ADAMTS13 to undergo autolysis at low pH may result in a transient decrease in active 
enzyme immediately following exercise. It has been shown that habitual physical 
exercise is associated with an overall decreased risk of acute heart disease. However, 
intense exercise may trigger acute myocardial infarction20. A number of studies have 
shown that strenuous physical exercise resulted in an activation of the hemostatic 
system20. One study, using human volunteers, investigated the effect of moderate and 
strenuous exercise on experimental arterial thrombus formation in men21. 
Thrombogenesis was measured in 15 sedentary healthy male volunteers at rest or 
immediately after exercise tests. The results showed that moderate exercise did not affect 
arterial thrombus formation. However, exercise of heavy intensity (conditions under 
which acidosis is likely to occur) was shown to increase the risk for arterial thrombosis21. 
These findings, combined with to potential of ADAMTS13 to engage in autolysis at low 
pH and high ionic strength conditions, may be able to shed light on explaining the 
potential susceptibility to arterial thrombosis with heavy exercise. 
6.2.5 The in vivo correction of platelet and fibrin accumulation with infused ADAMTS13 
suggests the importance of ADAMTS13 localization 
The data presented in Chapter 5, along with published data from Xiao et. al.22, 
demonstrate the direct correlation between anti-arterial thrombotic activity of 
ADAMTS13 (or variants) and its VWF-cleavage activity under fluid shear stress, 
suggesting the critical role of ADAMTS13-mediated VWF proteolysis in modulation of 
arterial thrombosis. With growing interest in the therapeutic potential of recombinant 
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ADAMTS1323 or gene transfer24 in TTP and many other diseases, the findings showing 
the change in thrombus morphology and composition may provide the molecular basis 
for rational design of therapeutic targets. 
The most rational thought when considering these results is whether determining the 
kinetics of platelet and fibrin accumulation from the head to the tail of the thrombus is a 
fruitful exercise. I contend that this knowledge is essential to the hypothesis, given the 
nature of the carotid artery occlusion model. Presumably, the FeCl3 model derives its 
usefulness from the ability to cause a targeted mechanical injury to a specific site in the 
vessel. This allows for the spread of a thrombus from this site of injury, effectively 
creating a gradient of VWF, fibrin, and platelet concentrations. By virtue of the fact that 
ADAMTS13 is expressed in regions specifically where it is needed, it is reasonable that 
the gradient of ADAMTS13 across a thrombus moves more slowly than the gradient of 
VWF, effectively allowing for the accumulation of platelets without allowing 
uncontrolled aggregation. It is, thus, important to study the differential kinetics of platelet 
and fibrin accumulation to ensure that exogenously-expressed ADAMTS13 follows a 
similar gradient to the endogenous ADAMTS13. Whereas our current experiments have 
indicated that this may be an issue22, we must endeavor to create ways to specifically 
target the delivered ADAMTS13, whether through ectopic expression in platelets, or by 
addition of chemical moieties to target the enzyme to platelet surface glycoproteins. 
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6.3 Future Plans 
 
6.3.1 Improvement of methods to determine kinetics of VWF proteolysis 
A major limitation of the Western blot assay to quantify VWF cleavage by ADAMTS13 
is that detection of the 350 kDa dimer requires simultaneous cleavage of scissile bonds in 
adjacent subunits. However, only one cleavage event is required to decrease multimer 
size. The fractional saturation of VWF with FVIII or platelets in our reactions is likely 
small, thus a “double cleavage” event is unlikely, and we are likely underestimating the 
true magnitude of the rate of proteolysis by ADAMTS13. Consumption of multimers to 
lower molecular weight species requires a single cut, while accumulation of monomer 
largely requires two or more depolymerization events. It would be prudent to develop an 
assay that can detect single cleavage events to establish the magnitude of the rate 
enhancing effect of cofactors on VWF proteolysis and to provide a more meaningful 
measurement of ADAMTS13 function. 
Our novel ELISA-based assay presented in Chapter 3 detects the N-terminal peptide (i.e. 
EQAPNVY) resulting from cleavage after the Tyr residue occurring anywhere along a 
VWF multimer, which dramatically increases the assay sensitivity. Furthermore, the 
assay is highly specific for detecting the ADAMTS13 cleavage product, but not from the 
cleavage by other leukocyte proteases such as cathepsin G, proteinase 3, and elastase. 
Although this assay presents a potentially useful assay, it is limited in its applicability 
because of the potential interference of the assay by platelet cofactors. We, thus, have 
endeavored to design an even better assay to probe VWF cleavage by ADAMTS13. 
163 
 
Multimeric VWF contains free thiols at both amino terminal (D’D3 domain) and 
carboxyl-terminal (C domain) ends1. The perceived experiment is that one end of the 
VWF may be attached to a magnetic amine-derivatized beads and the other end of VWF 
may be attached to maleimide-biotin. This is possible because the estimated free thiols 
are much less than the number of protomers within a multimer1. By separating the 
magnetic bead-labeled VWF and detecting the cleaved biotin-labeled VWF, this strategy 
could simplify detection and provide more sensitive quantitative estimation of single 
VWF cleavage events by ADAMTS13. The thiols would be labeled with magnetic 
amine-derivatized beads using the compound N-succinimidyl-3-(2-pyridyldithio)-
propionate (SPDP), an amine reactive N-hydroxysuccinimide (NHS) ester that reacts 
with amine groups to form an amide bond25. The spacer arm of SPDP contains a pyridyl 
disulfide group that will react with sulfhydryls to form a reversible disulfide bond with 
the protein of interest. The remaining sulfhydryl group of VWF would then be labeled 
with biotin via its maleimide (NHS) group. The cleavage products, which would consist 
of various lengths of VWF can be detected by an ELISA format using a streptavidin- 
coated microtiter plate to capture the cleaved VWF fragments.  
The same approach to find potential exosites in Spa, described in Chapter 4, can be used 
to find potential exosites in other areas of ADAMTS13, particularly in the distal C-
terminal domains. These are particularly interesting because the C-terminus of globular 
VWF (the D4-CK domain) is able to interact with the C-terminal TSP1 5-8 repeats of 
ADAMTS13 in the absence of denaturants or shear stress7,8. It is reasonable to 
hypothesize that this initial contact serves as the “initial engagement” of VWF by 
ADAMTS13, and regulates VWF susceptibility to ADAMTS13 binding under the 
164 
 
application of further shear stress. Sequence alignments of the human ADAMTS13 TSP-
1 repeats (Figure 6.5) or the CUB domains (Figure 6.6) of various species indicate a 
similar pattern of sequence conservation that was observed with the identified Spa 
exosites. Identification of exosites in these distal C-terminal domains could provide 
information about differential specificity of ADAMTS13 for VWF under different shear 
environments. 
 
 
Figure 6.5. Sequence alignment of human ADAMTS13 TSP-1 repeats. An amino acid 
sequence alignment of human ADAMTS13 TSP-1 repeats indicates a consensus conserved region 
from residues 11 to 16 (CSVSCG) which may play an important role in initial substrate 
recognition. 
 
 
 
 
 
 
Figure 6.6. Sequence alignment of ADAMTS13 CUB domains from various species. An 
amino acid sequence alignment of ADAMTS13 CUB domains from various species indicates a 
consensus conserved region from residues 1215 to 1220 (AIGRPL) which may play an important 
role in initial substrate recognition. 
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6.3.2 Deciphering the relevance of ADAMTS13 autolysis 
In Chapter 4, the presumed autolytic activity of ADAMTS13 leaves room for many 
interesting questions. To probe the effects of various solution conditions on the proposed 
autolysis of ADAMTS13, we can set up conditions to screen the effect of pH, ionic 
strength, and hydrophobicity on ADAMTS13 autolysis. Although the determined 
boundaries of the solved structure were found to be from M432 (in TSP-1) to R670 (in 
Spa), we would also need to determine specific cleavage products resulting from 
ADAMTS13 autolysis. Perhaps the required fragment is the most abundant product, 
resulting in it consistently being the fragment that was able to crystallize. Preliminary 
identification of the cleavage products by western blotting, followed by detailed analysis 
of the exact cleavage products generated by mass spectrometry, can help us uncover this 
potentially exciting phenomenon. 
6.3.3 Achieving amino acid resolution of ADAMTS13 interactions 
In light of the importance of ADAMTS13 exosite binding presented in Chapter 4, along 
with the established importance of exosites in Spa for inhibitory autoantibody 
recognition, we can use our knowledge of crystallization of the ADAMTS13-CS 
fragment to undergo crystallization trials of ADAMTS13-CS bound to inhibitory 
antibodies. Our lab has isolated a repertoire of over 200 clones encoding single-chain 
fragments of variable region (scFV) by panning phage display libraries against full-length 
ADAMTS13 and a C-terminal fragment comprising of TSP1 5-8 and the CUB domains
26
. 
These monoclonal scFV(s) would be expressed in E. coli and purified, and the binding 
166 
 
epitopes of these monoclonal antibodies can be determined by crystallization of the 
antibodies in complex with ADAMTS13-CS. 
6.3.4 Rational design of ADAMTS13 for therapeutic purposes 
Ultimately, the information from these studies can be used to inform an intelligent design 
of ADAMTS13 that fulfills a core set of qualifications: 1) minimal construction, to allow 
for optimal delivery as a therapeutic; 2) sufficient activity, to allow for small amounts of 
the therapeutic to be delivered; 3) targetability, to allow for the addition of chemical 
moieties to target the enzyme to platelet or endothelial surface receptors; and 4) immune 
evasion, to allow the enzyme to be active, even in the presence of inhibitory antibodies. 
Distinct structural information about the ADAMTS13-VWF interface and the 
ADAMTS13-autoantibody interface can different approaches to protein design. I propose 
that a directed evolution approach, using a library of exosite mutants, can be used to 
initially identify desirable candidates. This can be followed by a chimeric approach, 
which would allow us to combine, delete, and replace domains in the enzyme candidates 
to design a minimal, effective enzyme. Using this enzyme candidate as the model, we can 
then develop de novo design techniques based on patient autoantibody screening. Once 
we know the profile of the patient antibodies, we can design enzymes that have perturbed 
or entirely missing epitopes. This methodology presents a new and exciting direction for 
research on ADAMTS13, which combines our studies of the basic biochemistry and 
structural biology of ADAMTS13 with protein engineering to develop a potentially 
useful therapeutic. 
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6.4 Conclusions 
 
The work presented in this thesis begins to tie together the complex nature of the 
association between VWF and ADAMTS13, which is controlled at multiple levels by 
mechanical, chemical, and allosteric factors. The ability of VWF to sense all of these 
contributions and allow itself to be optimally presented to ADAMTS13 is nothing short 
of fascinating. Shear stress is highest at the walls, where VWF can be optimally 
“stretched” to allow exposure of the ADAMTS13 cleavage bond. FVIII and platelet 
binding to VWF also occurs optimally where the lowest velocity occurs (at the vessel 
walls), further underscoring the importance of VWF to maintenance of hemostasis at the 
endothelium. Recruitment of FVIII and platelets by VWF not only allows for 
enhancement of ADAMTS13 activity, but it also allows for recruitment of clotting 
factors to the specific areas where they are needed. Thus, it becomes clearer why FVIII 
and platelets interact with VWF at such low densities—providing a restraint to the 
inherent feedback mechanisms of the coagulation cascade. 
The data presented in this thesis, along with data from Gao et. al.3, seem to suggest that 
substrate exosite binding between ADAMTS13 exosites in Spa and VWF-A2 are, to 
some extent, modular and portable. Efficient substrate cleavage, which in a typical 
system would likely be tightly regulated, does not depend on a fixed spacing between the 
scissile bond and distal residues that bind the Cys-rich and Spa domains. This has 
important consequences that arise from the ability of VWF to undergo many different 
conformational changes in the presence of varying amounts of shear stress and in 
different vessels. The ability to accommodate a large change in substrate structure 
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suggests that ADAMTS13 is a particularly flexible enzyme, and can alter the 
relationships among the various non-catalytic domains that bind VWF. It is likely that 
fluid shear stress introduces a variety of conformational changes in VWF rather than one 
well-defined substrate structure. In that case, stretched VWF multimers may expose a 
varying number of binding sites for ADAMTS13. The presence of multiple exosites in 
multiple domains becomes particularly important because of the potential heterogeneity 
in VWF conformations. 
This principle has particular usefulness when thinking about autoantibody binding of 
ADAMTS13. The large amount of VWF conformations available to ADAMTS13 may 
leave, at any particular time, some exosites that are unoccupied by VWF. These exosite 
regions, which are particularly surface-exposed and easily accessible by antibody 
variable fragment epitope recognition sites, likely have been targeted by these pathogenic 
antibodies. The very nature of VWF and blood vessel shear stress may be able to explain 
the effectiveness and somewhat odd inhibitory capacity of acquired TTP patient 
autoantibodies. 
Overall, the study of the combination of mechanical, chemical, and allosteric effects on 
VWF conformation and, subsequently, ADAMTS13 binding provides a massive 
contribution to the field of thrombosis research. This work serves as the foundation upon 
which we can study how proteins, in general, are not merely a product of specific 
interactions, but are controlled by many outside forces. With this knowledge, we can 
begin to decipher how nature can take advantage of this ability to modulate protein 
environments to allow optimal localization of proteins.  
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